

The Pharmacologist

Vol. 48
Number 3
2006
September

Experimental Biology 2007
Washington, D.C.
April 28 – May 2



Jefferson Memorial



Washington Convention Center



The Capital



Lincoln Memorial



White House

Inside this Issue:

- Message from President Sanders-Bush
- EB '07 Preliminary Program
- IUPHAR in Review
- ASPET Members Survey Results
- ASPET Centennial News



The PHARMACOLOGIST

News

<i>Message from Elaine Sanders-Bush</i>	page 79
<i>EB 07 Preliminary Program</i>	page 80
<i>GPCR Colloquium Preliminary Program</i>	page 90
<i>IUPHAR</i>	page 92

Features

<i>Journals</i>	page 94
<i>Public Affairs & Government Relations</i>	page 96
<i>Division News</i>	
<i>Division Executive Committees 2006-2007</i>	page 97
<i>Centennial Update</i>	page 99
<i>Members in the News</i>	page 101
<i>Staff News</i>	page 101
<i>New ASPET Members</i>	page 102
<i>Obituary – Deepak Bose</i>	page 106
<i>Obituary - Grant Robert Wilkinson</i>	page 107
<i>Death Notices</i>	page 108
<i>ASPET Members Survey Results</i>	page 109
<i>Chapter News</i>	
<i>Great Lakes Chapter Annual Meeting Summary</i>	page 112
<i>Mid-Atlantic Pharmacology Society Meeting Program</i> ..	page 114
<i>Southeastern Pharmacology Society Meeting Program</i> ..	page 115

Announcements

<i>Awards for EB 07</i>	
<i>Julius Axelrod Award</i>	page 116
<i>ASPET-Astellas Awards</i>	page 117
<i>Drug Metabolism Early Career Achievement Award</i> ..	page 117
<i>Benedict R. Lucchesi Distinguished Lectureship</i>	page 118
<i>Membership Information</i>	page 119

Reminder: Dues Notices for 2007 will be mailed this month!

The Pharmacologist is published and distributed by the American Society for Pharmacology and Experimental Therapeutics.

Editor

Suzie Thompson

EDITORIAL ADVISORY BOARD

Bryan F. Cox, Ph.D.
Ronald N. Hines, Ph.D.
Terrence J. Monks, Ph.D.

COUNCIL

President
Elaine Sanders-Bush, Ph.D.
President-Elect
Kenneth P. Minneman, Ph.D.
Past President
James E. Barrett, Ph.D.
Secretary/Treasurer
Lynn Wecker, Ph.D.
Secretary/Treasurer-Elect
Annette E. Fleckenstein, Ph.D.
Past Secretary/Treasurer
Patricia K. Sonsalla, Ph.D.
Councilors
Bryan F. Cox, Ph.D.
Ronald N. Hines, Ph.D.
Terrence J. Monks, Ph.D.
Chair, Board of Publications Trustees
Brian M. Cox, Ph.D.
Chair, Program Committee
Jack Bergman, Ph.D.
FASEB Board Representative
David B. Bylund
Chair, Long Range Planning Committee
Stephen G. Holtzman
Executive Officer
Christine K. Carrico, Ph.D.

The Pharmacologist (ISSN 0031-7004) is published quarterly in March, June, September, and December by the American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995. Annual subscription rates: \$20.00 for ASPET Members; \$45.00 for U.S. nonmembers and institutions; \$65.00 for nonmembers and institutions outside the U.S. Single copy: \$20.00. Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics, Inc. All rights reserved. Periodicals postage paid at Bethesda, MD. GST number for Canadian subscribers: BN:13489 2330 RT.

ASPET assumes no responsibility for the statements and opinions advanced by contributors to *The Pharmacologist*.

Deadlines for submission of material for publication: Issue 1, March 1; Issue 2, June 1; Issue 3, September 1; and Issue 4, December 1.

Postmaster: Send address changes to: *The Pharmacologist*, ASPET, 9650 Rockville Pike, Bethesda, MD 20814-3995.



MESSAGE FROM THE PRESIDENT



This is an exciting time for ASPET as we plan for our 100th birthday in 2008. Facing our second century, we cherish the past but recognize that change can be energizing and rejuvenating. The explosion of scientific knowledge creates significant opportunities that we must embrace. A sign of that is the recent renaming of one of our Divisions to explicitly recognize the emergence of pharmacogenomics.

Medical school curriculum revisions have created challenges for Pharmacology graduate programs with the elimination/curtailment of dedicated Pharmacology courses to accommodate organ-based instruction. Grassroots efforts by our members to promote graduate training in pharmacology are applauded; as a society, we have supported these efforts via our education committee, student travel awards, and education grants.

The ASPET Council continues to explore ways to serve our membership and to maximize our influence. Our journals have strong leadership, working to expand impact while insuring quality and integrity. As a society, we have championed pharmacological sciences, especially integrative/systems pharmacology, at the national level, educating policy leaders about the negative impact of NIH funding constraints and recent changes in the NIH grant review process. We also continually work to make the annual meeting a “must-attend” for pharmacologists. Maintaining the momentum for the Centennial celebration at the Spring 2008 meeting is one of our key responsibilities this year.

Another significant goal for the upcoming year is to increase our membership. Attracting new members is one way to rejuvenate and invigorate ASPET - I challenge each of you to bring in one new member this year. One of the privileges that we have as members of ASPET is the opportunity to nominate our colleagues for ASPET awards. This past year, we initiated two new awards, so that opportunity is further enhanced. The Axelrod Award was created in collaboration with the Catecholamine Club to honor Julius Axelrod’s scientific achievements. This year we also initiated the ASPET- Astellas Awards, which recognize translational pharmacology - research that is poised to have an impact in improving the health of our nation.

In closing, I want to thank you for the honor of serving as President of ASPET. As we review our priorities, I welcome your thoughts and involvement. Please let me know if you want to get more involved and what your specific interests are.

A handwritten signature in black ink that reads "Claire Farber". The signature is written in a cursive, flowing style.



**ASPET's Preliminary Program
Experimental Biology 2007
Washington, D.C.
April 28 – May 2**

■ SYMPOSIA ■

SYMBOLS KEY

- **A junior speaker will be selected from the contributed abstracts to give a short talk in this symposium**
- P** **Pharmacogenomics Theme**
- D** **Developmental Pharmacology Theme**
- TBD** **To be decided**

SUNDAY, April 29, 9:30 AM – 12:00 PM

Cannabinoids and Endocannabinoids I: Pain and Obesity

Chair: Aron H. Lichtman and Jenny L. Wiley

Overview.

Jenny L. Wiley, *Virginia Commonwealth University*

Elucidating the role of the endocannabinoid system in stress-induced analgesia.

Andrea G. Hohmann, *University of Georgia*

Endocannabinoid modulation of pain and inflammation.

Aron H. Lichtman, *Virginia Commonwealth University*

Development of the CB1 receptor antagonist rimonabant for the treatment of obesity-associated metabolic syndrome.

Gérard Le Fur, *Sanofi Aventis*

Development of selective FAAH and MGL inhibitors to treat pain and psychiatric disorders.

Daniele Piomelli, *University of California, Irvine*

● **Higher Order Organization of GPCR Signaling Components: Lipid Rafts and Multimeric Protein Complexes**

Chair: Rennolds S. Ostrom

Cyclic AMP compartmentalization, insights from calcium-sensitive adenylyl cyclases and key supporting players.

Dermot M.F. Cooper, *University of Cambridge*

GPCR interactions with PDZ scaffolds.

Randy A. Hall, *Emory University School of Medicine*

Localization of GPCR signaling components in caveolin-rich domains.

Paul A. Insel, *UCSD*

Regulation of G protein signaling by cytoskeletal components and membrane microdomains.

Mark M. Rasenick, *University of Illinois at Chicago College of Medicine*

P **Pharmacogenomics: Frontiers to the Future**

Chairs: Rochelle M. Long and Richard M. Weinshilboum

Cytochrome P450 pharmacogenomics: Molecular mechanisms.

Michel Eichelbaum, *Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart*

Priorities and standards in pharmacogenetics research.

David B. Goldstein, *Duke University*

The future of anti-hypertensive pharmacogenetics.

Donna K. Arnett, *University of Alabama*

Genetically-modified animal models for pharmacogenomics research.

Stephen B. Liggett, *University of Maryland*

Platforms for pharmacogenomics research and clinical applications.

Michael S. Phillips, *McGill University and Genome Quebec Innovation Center*

• **D** **Nicotine Modulates Adolescent Brain Plasticity: Molecular, Neurochemical and Behavioral Changes**

Chairs: Shannon G. Matta, Burt M. Sharp, and Frances M. Leslie

Gestational nicotine exposure alters adolescent mesolimbic dopamine release and nicotinic receptor expression.

Burt M. Sharp, *University of Tennessee Health Science Center*

Differential neuroadaptations to nicotine in adolescent and adult rats.

Sari Izenwasser, *University of Miami School of Medicine*

Nicotine interaction with other drugs during sensitive developmental periods.

Frances M. Leslie, *University of California, Irvine, School of Medicine*

Cognitive defects emerging during smoking and smoking withdrawal in adolescents with prenatal exposure to active maternal smoking.

Shannon G. Matta, *University of Tennessee Health Science Center*

Memory deficits emerging during nicotine withdrawal in adolescents with gestational exposure to maternal smoking.

Leslie K. Jacobsen, *Yale University School of Medicine*

• **Technology Series: Nanotechnology in Disease Therapeutics**

Chair: Shiladitya Sengupta

Diverse applications of bio-nanotechnology.

TBD

Nanostructures through self-assembly of biomolecules.

TBD

Nanotechnology in biology and biomedicine.

TBD

Nanodelivery devices for targeting complex diseases.

Shiladitya Sengupta, *Harvard Medical School/Brigham and Women's Hospital*

[SUNDAY, April 29, 3:00 – 5:30 PM](#)

Cannabinoids and Endocannabinoids II: Response to Pathogenic Processes

Chairs: Ben A. Bahr and Somnath Mukhopadhyay

Activation of CB1 cannabinoid receptor: Structural studies.

Alexandros Makriyannis, *Northeastern University*

Endocannabinoid anandamide in neuroprotection and angiogenesis: Interplay between CB1R and anandamide receptor.

Somnath Mukhopadhyay, *North Carolina Central University*

The endocannabinoid system in neurodegenerative disorders: beneficial or noxious?

Vincenzo Di Marzo, *Institute of Biomedical Chemistry, Pozzuoli, Italy*

Cellular and functional protection through dual modulation of the endocannabinoid system.

Ben A. Bahr, *University of Connecticut*

Behavioral and neurobiological significance of cannabinoid action.

Sam Deadwyler, *Wake Forest University School of Medicine*

Novel role of cannabinoid in the regulation of inflammation.

Prakash Nagarkatti, *University of South Carolina School of Medicine*

• **P** **Genetic Regulation of GPCR/G-Protein/Adenylyl Cyclase Signaling in Humans: Implications for Drug Actions**

Chair: Ross D. Feldman

Genetic variants of GPCRs linked to adenylyl cyclase activation.

Paul A. Insel, *UCSD*

Genetic variants of GRK: Pathophysiological implications.

Pedro A. Jose, *Georgetown University*

Adenylyl cyclase variants: Implications in cardiovascular/metabolic diseases.

Ross D. Feldman, *Robarts Research Institute*

G-protein variants.

Wilfred Siffert, *University of Essen*



P Pharmacogenomics 101: Incorporating the Current Issues into the Curriculum

Chair: Jack W. Strandhoy

Introduction.

Jack W. Strandhoy, *Wake Forest University School of Medicine*

Basic pharmacogenetics and molecular modeling.

Russ B. Altman, *Stanford University School of Medicine*

Therapeutic implications of pharmacogenomics: An overview.

Alan R. Shuldiner, *University of Maryland School of Medicine*

Ethical and legal implications of pharmacogenomics.

Paul R. Wolpe, *University of Pennsylvania School of Medicine*

Incorporating pharmacogenomics into the professional and graduate curricula.

Daniel A. Brazeau, *University of Buffalo - SUNY*

• **No Time to Be "Bad To the Bone:" Osteoporosis and Bone Research in 2007**

Chairs: Henry U. Bryant and Laura K. Nisenbaum

Current status of osteoporosis: The disease, therapies, outlook.

TBD

Important signal transduction pathways in the osteoblast.

Paula H. Stern, *Northwestern University Medical School*

Effect of PTH on osteoblast differentiation.

TBD

Stromal cell differentiation into osteoblasts.

TBD

Toxicology of Nanomaterials

Chairs: Nancy A. Montiero-Riviere and Marc W. Fariss

Nanostructures and health - Nanochemistry perspectives.

Kevin D. Ausman, *Rice University*

Biological effects of nanomaterials in skin.

Nancy A. Montiero-Riviere, *North Carolina State University*

Respiratory toxicity of single-walled carbon nanotubes.

Anna A. Shvedova, *NIOSH, Morgantown, WV*

Peripheral microvascular effects of pulmonary exposure to ultrafine particles.

Timothy R. Nurkiewicz, *West Virginia University*

Cardiovascular Gene Therapy

Chair: Paul L. Hermonat

Gene therapy against atherosclerosis.

Jawahar L. Mehta, *University of Arkansas for Medical Sciences*

Gene therapy for lung and cardiovascular disease.

Arthur L. Beaudet, *Baylor College of Medicine*

Cardiovascular gene therapy.

Joseph C. Glorioso, *University of Pittsburgh School of Medicine*

DNA virus as vectors for cardiovascular diseases.

James M. Wilson, *University of Pennsylvania*

MONDAY, April 30, 9:30 AM – 12:00 PM

• **D Child and Adolescent Depression: Why Do Kids and Adults Respond Differently to Antidepressants?**

Chair: David B. Bylund

Introduction.

David B. Bylund, *University of Nebraska Medical Center*

Behavioral neuropharmacology of adolescent brain development.

Christopher J. Kratochvil, *University of Nebraska Medical Center*

Behavioral neuropharmacology of adolescent brain development.

Linda P. Spear, *SUNY-Binghamton*



Issues in developing drugs specifically for children and adolescents.

TBD

Animal models of juvenile depression.

Kevin H. Happe, *Creighton University School of Medicine*

• **Posttranscriptional Regulation of Gene Expression**

Chair: J. David Port

Posttranscriptional regulation of gene expression: A regulatory paradigm for G-protein coupled receptors.

J. David Port, *University of Colorado Health Sciences Center*

Role of TTP in modulation of TNF alpha expression.

Perry J. Blackshear, *NIEHS, NIH, Research Triangle Park, NC*

MAPK-dependent phosphorylation of mRNA binding proteins and regulation of myogenic transcripts.

Roberto Gherzi, *National Institute for Cancer Research, Genoa, Italy*

Post-transcriptional regulation of cyclin expression in breast cancer.

Rebecca S. Hartley, *University of New Mexico Health Science Center*

P Cardiovascular Pharmacogenomics: From Theory to Practice?

Chair: Dan M. Roden

Genetics and genomics of antiarrhythmic therapy.

Dan M. Roden, *Vanderbilt University School of Medicine*

Genetic and genomic markers of response to antihypertensive therapy.

Julie A. Johnson, *University of Florida*

Predicting drug response in hypercholesterolemia.

Ronald M. Krauss, *Children's Hospital Oakland Research Institute*

Pre-prescription genotyping in heart failure: a concept whose time is near?

Michael R. Bristow, *University of Colorado Health Science Center*

Ray Fuller Symposium: Promise and Pitfalls in the Search for New Drugs Targeted at Metabotropic Glutamate Receptors

Chair: Darryle D. Schoepp

mGluR5 negative allosteric modulators: in line for multiple clinical proof of concept testing.

Vincent Mutel, *Addex Pharmaceuticals, Plan Les Ouates, Switzerland*

Roles of mGluRs in synaptic plasticity: implications for therapeutic interventions.

Graham L. Collingridge, *University of Bristol, U.K.*

Allosteric potentiators of metabotropic glutamate receptors as a novel approach for treatment of CNS disorders.

P. Jeffrey Conn, *Vanderbilt University*

mGlu receptors: Beyond the regulation synaptic transmission.

Ferdinando Nicoletti, *University of Catania, Italy*

MONDAY, April 30, 3:00 – 5:30 PM

Early Clinical Development Strategies for Monoclonal Antibody Experimental Agents in Non-Oncology Indications

Chair: Mary A. Mascelli

Anti IL-12/23 monoclonal antibody for psoriasis: Biomarker validation of mechanism-of-action and disease pathogenesis.

Kevin D. Cooper, *Case Western Reserve University and University Hospitals of Cleveland*

Early development of drugs with new mechanisms of action. Question-based rather than study-based development.

Adam F. Cohen, *Center for Human Drug Research, Leiden, The Netherlands*

Immune response analysis for monoclonal antibodies in development: Past experience and new expectations.

Carrie L. Wagner, *Centocor, Inc.*

Regulatory considerations related to the design of early clinical trials of monoclonal antibody experimental agents.

Libero Marzella, *FDA*

P Recent Advances in our Understanding of the Flavin-containing Monooxygenases: Role in Disease and Adverse Drug Reactions: *In Memory of Daniel Ziegler*

Chairs: Ronald N. Hines and David E. Williams



Introduction/Overview and dedication to Daniel M. Ziegler.

Fred F. Kadlubar, *NCTR, FDA, Jefferson, AR*

Developmental expression of FMO1 and FMO3: Mechanisms and variability.

Ronald N. Hines, *Medical College of Wisconsin*

FMO genetic polymorphisms and impact on function.

Elizabeth A. Shephard, *University College London*

FMO and drug hypersensitivity.

Craig K. Svensson, *University of Iowa College of Pharmacy*

Summary and future direction of FMO research.

David E. Williams, *Oregon State University*

• **Imaging Localized cAMP Signaling Dynamics Organized by AKAP Scaffold Proteins and Phosphodiesterases**

Chair: Mark L. Dell'Acqua

Regulation of neuronal PKA signaling by AKAP targeting dynamics.

Mark L. Dell'Acqua, *University of Colorado at Denver Health Sciences Ctr.*

Coordination of multiple cell signaling pathways in cardiac myocytes by AKAP scaffold complexes.

John D. Scott, *Oregon Health Sciences University*

Local cAMP signaling regulation of T-cell activation.

Kjetil Tasken, *University of Oslo*

Imaging local cAMP and PKA dynamics in cardiac myocytes.

Manuela Zaccolo, *University of Padua, Italy*

TUESDAY, May 1, 9:30 AM – 12:00 PM

D Molecular Mechanisms of Teratogenesis

Chair: Peter G. Wells

Oxidative DNA damage and repair in teratogenesis.

Peter G. Wells, *University of Toronto*

Oxidative stress and signal transduction in teratogenesis.

Jason Hansen, *Emory University School of Medicine*

Oxidative stress in diabetic teratogenesis.

Mary R. Loeken, *Harvard University*

Neonatal apoptotic mechanisms of neurodevelopmental deficits.

John W. Olney, *Washington University School of Medicine*

• **Regulation of Drug Metabolizing Enzymes and Transporters in Inflammatory Disease States: A Symposium in Honor of the Career of Dr. Kenneth W. Renton**

Chair: Edward T. Morgan

Overview and tribute to the contributions of Dr. Kenneth W. Renton.

Edward T. Morgan, *Emory University*

Inflammation and infection: Hazards for drug safety.

Kenneth W. Renton, *Dalhousie University*

Regulation of cytochrome P450 and UGT enzymes in live and sterile models of infection.

Edward T. Morgan, *Emory University*

Regulation of drug transporters in inflammation.

Micheline Piquette-Miller, *University of Toronto*

Repression of CYP3A4 by inflammation associated with cancer.

Graham Robertson, *University of Sydney*

Regulation of CYP3A metabolism and P-glycoprotein-mediated drug transport during CNS inflammation.

Kerry B. Goralski, *Dalhousie University*

• **P Impact of Pharmacogenomics on the Treatment of Neuropsychiatric Disorders: From Drug Target to Targeted Therapy**

Chair: Laura K. Nisenbaum

Genetic variants associated with neuropsychiatric disease susceptibility



David Goldman, *NIAAA, NIH*

Current applications of pharmacogenetic testing in antidepressants and antipsychotic treatment: Focusing on CYP2D6 and CYP2C19

Jose de Leon, *University of Kentucky*

Genetic variation and response to antidepressants.

TBD

From genome scan to functional biology for antipsychotic-induced weight gain.

Laura K. Nisenbaum, *Eli Lilly and Company*

TUESDAY, May 1, 3:00 – 5:30 PM

• **Multiple Calcium Channels in the Vasculature: Regulation of Arterial Tone**

Chair: Joseph E. Brayden

Store-operated Ca²⁺ influx in vascular smooth muscle: Role of Ca²⁺-independent phospholipase A2.

Victoria M. Bolotina, *Boston University School of Medicine*

Contributions of TRP channels to control of vascular cell calcium.

Donald L. Gill, *University of Maryland School of Medicine*

Regulation of arterial tone by calcium channels, potassium channels and ryanodine receptors.

Luis F. Santana, *University of Washington*

Roles of TRP channels in regulation of calcium homeostasis in resistance artery smooth muscle.

Joseph E. Brayden, *University of Vermont*

□ **Mouse Meets Man: Advanced Murine Models for Use in Cancer Drug Development**

Chairs: Thomas C. Stover and David Tuveson

Genetically engineered mouse models of pancreatic exocrine cancer.

David Tuveson, *University of Pennsylvania School of Medicine*

The differential effects of mutant p53 alleles on advanced murine lung cancer.

TBD

Modeling the role of BRCA1, BRCA2, and Trp53 loss-of-function in breast cancer.

Jos Jonkers, *Netherlands Cancer Institute*

Applications of mouse glioma models in preclinical trials.

TBD

WEDNESDAY, May 2, 8:30 – 11:00 AM

• □ **Perinatal Stress Alters Drug Responses into Adulthood**

Chair: Mike J. Kuhar

Maternal separation as a perinatal stressor.

Darlene Francis, *University of California, Berkeley*

Maternal separation affects propensity to abuse drugs.

Mike J. Kuhar, *Emory University*

Effects of maternal separation on brain serotonin systems.

Aleksandra Vicentic, *Emory University/Yerkes Regional Primate Center*

Neonatal isolation as a model of stress and its effects on drugs in adulthood.

Therese A. Kosten, *Baylor College of Medicine*

Epigenetic mechanisms as candidates for long term changes in drug effects.

Moshe Szyf, *McGill University*

• **Nitric Oxide Deficiency and Cardiovascular Disease**

• □ **Genetic Variations in Regulatory Factors Affecting Drug Metabolism/Disposition**

Chair: Erin Schuetz

PPARG (peroxisome proliferator activated receptor gamma) variation may underlie response to TZD (troglitazone) therapy in women at risk for type 2 diabetes.

Richard M. Watanabe, *University of Southern California*

Genetic variation in CAR in human populations. **Jatinder K. Lamba**, *St. Jude Children's Research Hospital*



FXR: Interindividual polymorphisms and variation in FXR expression.

Richard B. Kim, *Vanderbilt University*

PXR: Genetic variants of PXR (NR112) and their implications in drug metabolism and pharmacogenetics.

Erin Schuetz, *St. Jude Children's Research Hospital*

• **Pharmacology and Signal Transduction of Taste**

Chair: R. Kyle Palmer

Coding of taste signaling from receptor to brain.

Robert F. Margolskee, *Mount Sinai School of Medicine*

Behavioral discrimination and neuronal coding of taste in rodents.

Alan C. Spector, *University of Florida*

Transient receptor potential (TRP) channels in taste signaling.

Robert W. Bryant, *Linguagen Corporation*

Effects of therapeutic drugs on taste and their impact on compliance and nutritional status.

Susan S. Schiffman, *Duke University Medical Center*

Mechanisms of Idiosyncratic Drug Reactions

Chairs: Cynthia Ju and Dennis R. Peterson

Animal models of idiosyncratic drug reactions.

Jack Uetrecht, *University of Toronto Faculty of Pharmacy and Medicine*

How do systemically administered drugs provoke reactions in the skin?

Craig K. Svensson, *University of Iowa College of Pharmacy*

Role of cytokines and other factors in determining susceptibility to drug-induced liver injury.

Lance R. Pohl, *NHLBI, NIH*

Cellular consequences of drug bioactivation.

B. Kevin Park, *University of Liverpool*

■ **DIVISION SESSIONS** ■

[SUNDAY, April 29, 9:30 AM – 12:00 PM](#)

Division for Pharmacology Education Symposium: Pharmacological Characterization of Genetically Modified Animal Models: The Fundamentals

Chair: William B. Jeffries

[MONDAY, April 30, 9:30 AM – 12:00 PM](#)

Division for Drug Discovery, Development, and Regulatory Affairs Symposium: Assessing Abuse Liability for Drug Discovery and Development: A Changing Environment

Chair: Richard H. Alper

Cellular and molecular mechanisms contributing to substance abuse.

Annette E. Fleckenstein, *University of Utah*

The translation and application of rodent models for abuse liability testing.

Andy Mead, *Pfizer, Ltd., Kent, U.K.*

Clinical abuse liability assessments.

Edward M. Sellers, *Ventana Clinical Research Corporation*

Regulatory environment in abuse liability assessments.

Douglas Throckmorton, *FDA*

[MONDAY, April 30, 3:00 – 5:30 PM](#)

Division for Behavioral Pharmacology Symposium: Its all the Rave: Behavioral, Neuropharmacological and Toxic Effects of MDMA and Methamphetamine

Chairs: Michael A. Nader and Matthew L. Banks

Tolerance to reinforcing and subjective effects of MDMA in humans.

Andrew C. Parrott, *University of Wales, Swansea*



The role of serotonin receptors in the behavioral pharmacology of MDMA.

Kathryn A. Cunningham, *University of Texas Medical Branch, Galveston*

MDMA- and MA-induced brain changes: Imaging studies in nonhuman primates and humans.

Una D. McCann, *Johns Hopkins University School of Medicine*

Neurochemical alterations and long-term consequences of MA and MDMA abuse.

Annette E. Fleckenstein, *University of Utah*

Ambient temperature interactions related to MDMA abuse; MDMA abuse and neurotoxicity as measured by PET.

Matthew L. Banks, *Wake Forest University School of Medicine*

Division for Cardiovascular Pharmacology Benedict R. Lucchesi Distinguished Lecture and Junior Scientists Competition

Chairs: David D. Ku and William M. Armstead

P Division for Toxicology Symposium: Toxicogenomics Approaches for Evaluating Drug and Chemical Toxicity

Chair: Curt J. Omiecinski

Gene expression profiling in primary human hepatocytes as predictors of interindividual variability in chemical response.

Curt J. Omiecinski, *Penn State University*

Application of toxicogenomics towards idiosyncratic hepatotoxicity.

Jeffrey F. Waring, *Abbott Laboratories*

The Comparative Toxicogenomics Database: Promoting understanding about the mechanisms of chemical actions.

Allan P. Davis, *Mount Desert Island Biological Laboratory, Salisbury Cove, ME*

Genetic and genomic approaches to predicting chemical toxicity.

Christopher A. Bradfield, *University of Wisconsin*

Data analytic platforms and methods for mining proteome data and its integration with genomic information.

Martin W. McIntosh, *Fred Hutchinson Cancer Research Center, Seattle*

TUESDAY, May 1, 9:30 AM – 12:00 PM

P Division for Clinical Pharmacology, Pharmacogenetics, and Translational Medicine Symposium: The Regulatory Approach to Pharmacogenomics: An International Perspective

Chairs: Lawrence J. Lesko and Felix W. Frueh

U.S. FDA regulatory approaches to pharmacogenomics.

Felix W. Frueh, *FDA*

Pharmacogenomics: A global view from a global company.

Celia Brazell, *GlaxoSmithKline*

Development of devices for pharmacogenomic testing.

Janet A. Warrington, *Affymetrix*

Drug-test co-development: A real-life perspective.

Jeffrey R. Gulcher, *deCODE Genetics*

Panel discussion. From science to regulation to medical practice: The challenge of implementation.

Larry J. Lesko, *FDA* and **Wayne A. Rosenkrans**, *AstraZeneca and Personalized Medicine Coalition*

Division for Molecular Pharmacology Postdoctoral Award Finalists

TUESDAY, May 1, 2:00 – 3:00 PM

Division for Drug Metabolism Early Career Achievement Award Lecture

Chairs: Larry S. Kaminsky and Kenneth E. Thummel

TUESDAY, May 1, 3:00 – 5:30 PM

Drug Metabolism Division Platform Session: Biotransformation and Drug Transport

Chairs: Larry S. Kaminsky and Kenneth E. Thummel



Division for Neuropharmacology Postdoctoral Scientist Award Finalists

Division for Systems and Integrative Pharmacology Symposium: Regenerative Pharmacology: Integrative Pharmacology of Engineered Tissue

Chair: George J. Christ

Regenerative pharmacology: An overview.

George J. Christ, *Wake Forest University*

Mechanical and matrix effects on cell phenotype in engineered cardiovascular tissues.

Jan P. Stegemann, *Rensselaer Polytechnic Institute, Troy, NY*

Challenges and opportunities in engineering clinically relevant bladder implants: The importance of pharmacology and phenotype.

Tim Bertram, *Tengion, Inc, Winston-Salem*

Pharmacology of engineered and regenerating tissues.

Karl-Erik Andersson, *Wake Forest University*

Cyclic GMP and vascular smooth muscle cell phenotype.

Thomas Lincoln, *University of South Alabama College of Medicine*

■ LECTURES AND SPECIAL SESSIONS ■

SATURDAY, April 28

12:30-3:00 PM

2007 Teaching Institute: Integrated Strategies in Pharmacology Education: Simulation, Case- & Team-Based Approaches

Chairs: Lynn M. Crespo and Jordan E. Warnick

Overview: Multiple approaches to the teaching of pharmacology.

Lynn M. Crespo, *University of South Florida* and **Jordan E. Warnick**, *University of Maryland School of Medicine*

Lecture-based approach to pulmonary pharmacology.

Jordan E. Warnick, *University of Maryland School of Medicine*

Simulators in acute asthma case (albuterol and steroids).

John L. Szarek, *Ross University School of Medicine*

Case-based approaches in pulmonary disease.

Lynn M. Crespo, *University of South Florida*

Team-based approach to pulmonary pharmacology.

Robert J. Theobald, *A.T. Still University*

1:00-3:15 PM

Graduate Student-Postdoctoral Colloquium: Pharma Phair

Chairs: Stephanie W. Watts and Walter C. Prozialeck

Trainees will first hear, then interact with, professionals from different career paths to view the wide variety of options open to them after graduate school.

Academician:

Barbara S. Beckman, *Tulane University School of Medicine*

Teacher:

Walter C. Prozialeck, *Midwestern University*

Consultant:

Marie T. Rock, *Chirality, LLC*

Legal:

Blair E. Taylor, *Venable LLP*

NIH:

Lance R. Pohl, *NIH, NHLBI*

Pharmaceutical Industry:

Ryan M. Fryer, *Abbott Laboratories*

Pharmacy:

Rangaprasad Sarangarajan, *Massachusetts College of Pharmacy*

Public Affairs:

James S. Bernstein, *ASPET*

Scientific Writing:

Jill U. Adams, *Albany, NY*

Scientific Officer:

Christine K. Carrico, *ASPET*

Biotech:

Michael Babich, *ImmvaRx*



[3:15-5:30 PM](#)

Workshop: Mentoring: How to Find a Good Mentor and How to Be a Good Mentor

Chairs: Martha I. Dávila-García and Gonzalo E. Torres

How to find a good mentor. **Howard G. Adams**, H.G. Adams and Associates, Inc.

How to be a good mentor. **James G. Townsel**, Meharry Medical College

[SUNDAY, April 29](#)

[8:15-9:15 AM](#)

Julius Axelrod Award Lecture

[1:30-2:30 PM](#)

Torald Sollmann Award Lecture

[MONDAY, April 30](#)

[8:00-10:00 AM](#)

ASPET/APS Women's Committees Workshop: Being Heard: The Microinequities That Tilt the Playing Field

Chairs: Susan F. Steinberg, Holly H. Brevig and Kathleen H. Berecek

[8:15-9:15 AM](#)

Ray Fuller Lecture in the Neurosciences: Case Study from Bench to Bedside: Modulators of mGlu2 and mGlu3 Receptors to Treat Psychiatric Disorders

Lecturer: Darryle D. Schoepp

[12:45-1:45 PM](#)

EB 2007 Public Policy Session: NIH at the Crossroads: How Diminished Funds Will Impact Biomedical Research and What Scientists Can Do About It

Chair: Leo T. Furcht

Speakers:

Elias Zerhouni, *NIH Director*

John E. Porter, *Hogan & Hartson and former Chair of US House of Representatives Labor/HHS Appropriations Subcommittee*

Rep. Porter will provide a legislative overview of the FY 2008 outlook for the NIH. He will discuss how scientists have an obligation as citizens to become politically active and aware and make suggestions for what needs to be done to make an impact. Dr. Zerhouni will provide details on the current state of the NIH enterprise and offer projections based on the FY 2008 budget.

■ **SATELLITE MEETINGS** ■

[FRIDAY, April 27 – Saturday, April 28](#)

3rd GPCR Colloquium

(Separate, Advance Registration Required)

Program details on page 90

[FRIDAY, April 27 – Saturday, April 28](#)

Behavioral Pharmacology Society Meeting

(Separate, Advance Registration Required)

Contact Galen R. Wenger: grwenger@uams.edu or 501-686-8040



3rd G Protein Coupled Receptors Colloquium

FRIDAY-SATURDAY, APRIL 27-28, 2007
WASHINGTON, DC

ORGANIZED BY: KIM A. NEVE, PH.D. AND OLIVIER CIVELLI, PH.D.

Sponsored by the ASPET Division for Molecular Pharmacology
This is a satellite meeting to Experimental Biology '07.

Additional speakers will be selected from abstracts contributed to the GPCR Colloquium.

Friday, April 27
8:00 AM - 5:00 PM

The structural basis for GPCR oligomerization: Implications for activation

Jonathan A. Javitch, *Columbia University College of Physicians and Surgeons*

Heterooligomerization of Class A GPCRs creates novel signaling units distinct from their constituent GPCR homooligomers

Susan R. George, *University of Toronto*

GPCR ligand binding and release: Insights and mysteries

David L. Farrens, *Oregon Health and Science University*

G proteins and their accessory proteins

Stephen M. Lanier, *Louisiana State University*

Interactions between GPCRs and receptor tyrosine kinases

Kevin J. Catt, *NICHHD, NIH*

GPCRs, arrestins, and ubiquitination

Sudha K. Shenoy, *Duke University Medical Center*

Multiplexing resonance energy transfer approaches to study GPCR signaling complexes in living cells

Michel Bouvier, *University of Montreal*

Use of genetically engineered mice to unravel the functions of dopamine receptors

Emiliana Borrelli, *University of California, Irvine*

Saturday, April 28
8:15 AM - 4:30 PM

Kisspeptin and GPR54 in the regulation of puberty and reproduction

Ursula Kaiser, *Brigham & Womens Hospital, Harvard Medical School*

GPCRs in arousal and anxiety

Rainer K. Reinscheid, *University of California, Irvine*

The role of GPR30 in estrogen signaling

Eric R. Prossnitz, *University of New Mexico Health Sciences Center*

Therapeutic benefits of inverse agonism at cannabinoid receptors

Gerard Le Fur, *Sanofi-Aventis*

Novel aspects of the melanocortin receptors

Roger D. Cone, *Oregon Health and Science University*

Leucocyte chemoattractant receptors: New molecules and new concepts

Marc Parmentier, *Free University of Brussels*

Special Lecture

The function and regulation of G protein coupled glutamate receptors in the neural network

Shigetada Nakanishi, *Osaka Bioscience Institute*

Continental breakfast and lunch will be provided both days.

Registration deadline is **April 6, 2007**

Register online at: http://www.aspet.org/public/meetings/GPCR_regform.pdf



3rd G Protein Coupled Receptors Colloquium Registration Form

FRIDAY-SATURDAY, APRIL 27-28, 2007
WASHINGTON, DC

ORGANIZED BY: KIM A. NEVE, PH.D. AND OLIVIER CIVELLI, PH.D.

Sponsored by the ASPET Division for Molecular Pharmacology
This is a satellite meeting to Experimental Biology '07

YOU CAN REGISTER IN THE FOLLOWING WAYS BEFORE APRIL 6, 2007

WEB: [HTTP://WWW.ASPET.ORG/PUBLIC/MEETINGS/MEETINGS.HTML](http://www.aspet.org/public/meetings/meetings.html)

MAIL: ASPET, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814

FAX: 301-634-7061

NAME/TITLE: _____
FIRST LAST TITLE

COMPANY/INSTITUTION: _____

ADDRESS: _____

E-MAIL: _____ PHONE: _____ FAX: _____

I WANT TO PRESENT A POSTER AND BE CONSIDERED FOR A SHORT TALK.
(PLEASE ENCLOSE THE ABSTRACT AND ALSO EMAIL TO: MARKIN@ASPET.ORG)

ADVANCED REGISTRATION FEES (FEES INCLUDE CONTINENTAL BREAKFAST AND LUNCH):
ASPET MEMBERS \$250.00 (U.S.)
NON-MEMBERS \$375.00 (U.S.)
STUDENTS/POSTDOCTORAL FELLOWS \$ 80.00 (U.S.)

ON-SITE REGISTRATION: ASPET MEMBERS/NONMEMBERS - \$500; STUDENTS - \$200

TOTAL ENCLOSED (US \$): \$ _____ MAKE CHECK PAYABLE TO: **ASPET**
OR

BILL MY CREDIT CARD FOR: \$ _____

CREDIT CARD: VISA MASTERCARD AMERICAN EXPRESS

ACCOUNT NUMBER: _____ EXPIRATION DATE: _____

SECURITY CODE: _____ (3 DIGITS ON BACK OF VISA/MASTERCARD; 4 DIGITS ON FRONT OF AMEX)

SIGNATURE: _____
I AUTHORIZE ASPET TO SIGN ON MY BEHALF

NAME AS IT APPEARS ON CARD: _____
PLEASE PRINT



Registrants with special needs, please contact
ASPET's Meetings Assistant, Margie Arkin, at 301-634-7060.

The **15th World Congress of Pharmacology** was held in Beijing, China, July 2-7, 2006. The congress was attended by over 2,000 scientists from around the world. The 265 registrants from the U.S. included seven James A. Bain Young Scientist Travel Award winners and ten Graduate Student Travel Award winners from ASPET in addition to ASPET's ten official delegates to the IUPHAR General Assembly. Elaine-Sanders Bush, Richard Weinshilbourn, and Lorraine Gudas gave plenary lectures, and Terry Kenakin presented the IUPHAR Lecture in Analytical Pharmacology. While not without some logistical problems, particularly with the online registration system, the Congress overall ran very smoothly. In large part, this was due to the host of pharmacology graduate student volunteers who handled on-site registration, audio-visual assistance, and any other tasks that needed attention. You could recognize these cheerful, helpful volunteers by their yellow sports shirts with the green congress logo.

The Program consisted of 23 plenary lectures and symposia with 264 invited speakers from around the world. Program topics covered the range from molecular through clinical pharmacology and from the pharmacology of traditional medicines to gene- and cell-based therapies for disease. Many of the topics are ones of critical interest to scientists worldwide but are not traditionally covered at domestic U.S. meetings (e.g. malaria therapy, traditional medicine, chronopharmacology). There were several sessions focusing on regulatory issues as well as on education.



Opening ceremony of the 15th World Congress of Pharmacology

Many of the topics are ones of critical interest to scientists worldwide but are not traditionally covered at domestic U.S. meetings (e.g. malaria therapy, traditional medicine, chronopharmacology). There were several sessions focusing on regulatory issues as well as on education.



Chinese student volunteers perform at the Opening Ceremony

The Opening Ceremony featured welcoming remarks not only by the Congress President, Professor Lin Zhi Bin, and IUPHAR President, Paul Vanhoutte, but also by the Vice-Mayor of Beijing and the head of the Science and Technology Ministry. Following these remarks, a performance featured several different cultural activities of Beijing, including the Beijing opera, musicians, a Kung Fu demonstration and acrobatics. The student volunteers, wearing their signature yellow shirts and Levis, sang two songs that they had rehearsed specifically for this event. The Opening Ceremony was followed by a reception and outdoor buffet that featured many traditional Chinese dishes.

Other social highlights of the meeting included a reception celebrating the 75th anniversary of the British Pharmacological Society at which ASPET presented the BPS with a plaque honoring its birthday, a Peking Duck dinner following an evening tour of Ti'anmen Square, and the closing banquet at a traditional Chinese family



ASPET Past President, Jim Barrett presenting a congratulatory plaque to Graeme Henderson, President of the British Pharmacology Society at the reception celebrating its 75th anniversary

Other social highlights of the meeting included a reception celebrating the 75th anniversary of the British Pharmacological Society at which ASPET presented the BPS with a plaque honoring its birthday, a Peking Duck dinner following an evening tour of Ti'anmen Square, and the closing banquet at a traditional Chinese family



restaurant.

The IUPHAR General Assembly ratified its earlier electronic vote to change the name of the union to the International Union of Basic and Clinical Pharmacology, although the acronym (IUPHAR) will remain unchanged. South Africa was selected as the site of the 2014 WorldPharma Congress. ASPET member, Sue P. Duckles, the current IUPHAR Secretary-General, was elected to a four year term as President, succeeding Paul M. Vanhoutte. ASPET member, Sam Enna was elected to a four-year term as IUPHAR Secretary-General. Thus ASPET is well represented in the hierarchy of IUPHAR.

At the closing ceremony, IUPHAR presented several awards to young scientists.

The IUPHAR Young Scientist Award winners were:

- Gold – Rebecca Roof (USA)*
- Silver – Zhou Peng (China)*
- Bronze – Gregor Purves (UK)*

IUPHAR presented a new award for young investigators working in Natural Products this year:

- First place winner was Xu Yan-Chun (China).*
- Second place winners were Kim Sang-Hyun (Korea) and Noriko Yoshikawa (Japan).*
- Third place winners were Tseng Tzu-Ling (China), Zhu Lei (China), Selen Isbir-Soylemez (Turkey), and Jiang Ning (China).*

The Office of AIDS Research at NIH sponsored a Young Investigator Poster Award for Research on Drug Treatment of AIDS and AIDS-Associated Diseases. Winners were:

- Mi-Feng Liu (China), Zidek Zdenek (Czech Republic) and Nathan Erdmann (USA).*
- In addition, the AIDS Office presented a travel award to Jessica Gardner (USA).*

There were presentations from the sponsors of CPT'08 in Quebec City, July 27-August 1, and from the sponsors of WorldPharma 2010 in Copenhagen, July 17-23. The Congress aptly closed with the student volunteers singing *Auld Lang Syne*.



IUPHAR President, Sue Duckles and Secretary-General, Sam Enna, both past presidents of ASPET



Brian Cox, Suzanne Bausch, Elaine Sanders-Bush, and David and Elaine Bylund at the Opening Reception



The Chinese National Committee for IUPHAR 2006





2007 Subscription Prices Set

ASPET's Board of Publications Trustees met by conference call on June 12 to set the 2007 subscription prices for the Society's journals. The BPT reviewed the journals' financial statements for 2005 and subscription renewals for 2006, considered projections of pages to be published in 2006 and 2007, and analyzed whether open access to accepted author manuscripts in *JPET*, *MolPharm*, and *DMD* was having an impact on journal-related income.

The Society's publications program overall was in the black in 2005. Half of the net surplus was from investments. *Molecular Interventions* and *Drug Metabolism and Disposition* ran at a loss. Surpluses from the other journals plus investment income are used to cover these losses as well as support other Society activities that do not generate income.

Based on the financial and subscription information available, the BPT increased institutional and nonmember subscription rates by 4% for 2007. The differential between US and non-US prices will increase by 2%. The member price for a *DMD* print subscription will increase by 5% (from \$91 to \$96) and by 10% for *MolPharm* (from \$119 to \$131). These prices are roughly half of the non-member prices. There will be no increase to the 2007 member prices for *JPET* and *Pharmacological Reviews*. Members automatically receive *Molecular Interventions* as part of their membership.

Institutions have struggled to keep up with rising subscription rates, especially those of for-profit publishers. ASPET has kept its prices low but had to increase its rates more than usual over the last several years because of rapid growth among its journals. The number of pages published increased by 20% for some journals in some years. Institutional prices, however, increased by only single digits.

Modestly increased page charges and manuscript submission fees have also helped offset rising costs. The Journals Department has worked to attract new subscribers, particularly in Europe and Asia. This has kept subscription losses overall quite low.

Update on Open Access to ASPET's Journals

On April 28, 2005, ASPET began making manuscripts accepted for publication in *JPET*, *Molecular Pharmacology*, and *Drug Metabolism and Disposition* freely available immediately. These open access articles in the Society's three primary research journals appear online as "Fast Forward" articles. They are neither copyedited nor formatted, and they remain freely available after the final version goes online. ASPET makes all content in its five journals freely available 12 months after publication, as it has since 1999. IUPHAR nomenclature reports in *Pharmacological Reviews* are also made freely available immediately upon publication.

Applying open access to Fast Forward articles has allowed the Society to further test the open-access waters. Other nonprofit societies and for-profit commercial publishers are similarly experimenting with open access, experimenting with various publication models.

Many of the experiments focus on an author-pays model. In completely open access journals, authors are required to pay a publication fee to cover publication costs. This fee is expected to come out of research grants rather than library budgets. Those in developing countries are supposed to be granted fee waivers; one publisher has been accused of blocking papers from unfunded authors to avoid granting waivers. Hybrid models keep access controls and subscription prices in place but give authors the option of paying a fee to



Journals

make individual articles freely available immediately. Authors have demonstrated limited support for this model.

I do not know of any open access journal that is not operating at a loss. Some rely on grants. Others hope to significantly supplement author fees with revenue from advertising and commercial reprint sales to reach break-even but have yet to realize that goal.

For journals offering an optional open-access fee, uptake has been low. Oxford University Press recently released the first year results of its experiment with 49 titles across different disciplines. Thirty-six journals published author-paid, open-access articles. In a press release, Oxford explained that “The majority of uptake of optional open access has, as predicted, been in the life sciences, with approximately 10% of authors selecting the open access option across 16 participating journals in this area, compared with approximately 5% in medicine and public health, and 3% in the humanities and social sciences. Three life sciences titles in the areas of molecular and computational biology have seen over 20% uptake.”

The data so far on open access to accepted manuscripts in *JPET*, *MolPharm*, and *DMD* have been inconclusive. Subscription counts for 2006 are currently down by 5-8% from 2005 versus decreases of no more than 2% from 2004 to 2005. These are the largest decreases seen by ASPET in several years, but other factors could be affecting subscriptions. It is too early to tell if immediate open access to Fast Forward articles results in fewer subscriptions.

Pay-per-view income went down for *JPET* following the implementation of immediate Fast Forward open access, but it also went down for *Pharmacological Reviews* and *Molecular Interventions*, neither of which publishes Fast Forward articles. At the same time, pay-per-view income increased for *DMD* and *MolPharm*. The access-controlled archival issues that were added to the online journals do not account for this increase by themselves.

At this time, there are no clear indicators of what impact open access is having, either good or bad, on ASPET's journals. Our crystal ball remains as foggy as ever. We'll continue to monitor subscription and pay-per-view statistics for possible trends.

TAKE ADVANTAGE OF EMAIL ALERTS

A free service providing email-based alerts for ASPET's journals!

Customize alerts to meet your needs: Announcements, Future Table of Contents, Fast Forward Articles, Table of Contents, CiteTrack Alerts including Citation Alerts and Keyword & Author Alerts

Create your alerts at:

JPET.aspetjournals.org/subscriptions

PHARMREV.aspetjournals.org/subscriptions

MOLPHARM.aspetjournals.org/subscriptions

DMD.aspetjournals.org/subscriptions

MOLINTERV.aspetjournals.org/subscriptions





NIH Appropriations and Authorization

Congress will return September 15. The Senate Appropriations Committee recommended that NIH receive \$28.459 billion for FY'07. This \$220 million increase is only 0.78% more than its FY'06 appropriation. The full Senate is not expected to vote on this spending bill before the November elections – and the bill won't pass without additional funding for other health and education programs. In the House, the Labor/HHS spending bill is held up as House Republican moderates are unlikely to support a bill that would hurt health and education spending so severely. The most likely outcome in the Senate and House is that both bills will not even see floor action. Instead, they will move directly to a House-Senate conference following the elections.

Meanwhile, movement on the NIH reauthorization bill is also on hold until sometime after September 15. FASEB, AAMC, AAU and other organizations have been in negotiations with House Energy and Commerce Committee Chairman Joe Barton (R-TX) over some contentious issues. One of the main issues is that the as yet unseen bill might mandate that 50% of any NIH annual increase would be reserved for the NIH common fund, and the other 50% would be distributed across the rest of the NIH. This would continue until the common fund totaled 5% of NIH's total budget. This would obviously hamper the ability of institutes to grow and fund programs, something ASPET and other scientific societies would likely not support.

Preview of EB 2007 Public Affairs Activities, Washington, DC

ASPET members attending the Experimental Biology 2007 meeting in Washington, DC this spring will have the opportunity to participate in two public affairs activities.

NIH Director Elias Zerhouni and former House Appropriations Subcommittee Chair John Porter will speak about the "NIH at the Crossroads: How Diminished Funds Will Impact Biomedical Research and What Scientists Can Do About It." The talk is open to all EB registrants and will be held on Monday, April 30, from 12:45 – 1:45 pm in the Washington Convention Center. Dr. Zerhouni will provide his perspective and details on the current state of the NIH enterprise. Mr. Porter will provide a legislative overview of the FY 2008 outlook for the NIH. He will discuss how scientists have an obligation as citizens to become politically active and aware and make suggestions for what needs to be done to make an impact.

Also in the planning stages is EB Capitol Hill Days on April 30, May 1 and May 2. With scientists facing one of the most alarming periods to confront the biomedical research enterprise in recent years, ASPET and the other participating EB societies are encouraging their members to take advantage of a Washington meeting to promote biomedical research. Join us by making Capitol Hill visits during EB in support of increased funding for the NIH, NSF and other federal agencies. The convergence of over 10,000 of your scientific colleagues in the Nation's Capital provides a unique opportunity for constituent scientists to educate Members of Congress about the need to provide robust funding for the NIH and other agencies. The public affairs staff from the participating EB societies will be able to assist you in these meetings. More detailed information will be forthcoming in the coming months.

2006 Summer Short Courses in Integrative and Organ Systems Science

The past two summers, NIGMS has funded four short courses. These summer short courses will be offered again in 2007 at four institutions. The purpose of each short course is to introduce graduate students and Ph.Ds to the knowledge and skills needed for integrative studies of organ systems and intact animals and to the physiological and biochemical responses of these systems to drugs. These critical skills are in short supply. Graduate students and Ph.Ds. with these skills are in great demand in both academic and industrial settings. Graduate students and others interested in information on the 2007 summer workshops should visit: http://www.aspet.org/public/public_affairs/pa_NIGMS_shortcourse_awards.html

New Ephedra Rule Gives FDA Authority to Ban Supplements

A federal appeals court reversed a 2004 lower court decision that had lifted the FDA's earlier ban on Ephedra. The new ruling now gives FDA broad authority to pull Ephedra and other dietary supplements from the market if the risks outweigh its benefits. However, given FDA's financial constraints it is not certain how this new authority could be enforced.

New FASEB "Breakthroughs" Publication

FASEB has released "Breast Cancer, Tamoxifen and Beyond: Estrogen and Estrogen Receptors," the latest article in the *Breakthroughs in Bioscience* series. The *Breakthroughs in Bioscience* series is a collection of illustrated articles, published by FASEB, that explain recent developments in basic biomedical research and how they are important to society. To obtain a free copy of these publications, visit the *Breakthroughs in Bioscience* Web site (<http://opa.faseb.org/pages/Publications/breakthroughs.htm>) or contact FASEB's Office of Public Affairs at (301) 634-7650.



**DIVISION EXECUTIVE COMMITTEES
2006-2007**

DIVISION FOR BEHAVIORAL PHARMACOLOGY

Alice M. Young, *Chair* **
 Charles P. France, *Chair-Elect**
 Linda Dykstra, *Past Chair*
 Elise M. Weerts, *Secretary Treasurer*
 Leonard L. Howell, *Secretary/Treasurer-Elect*
 Kathleen M. Kantak, *Past Secretary/Treasurer*
 Emily M. Jutkiewicz, *Student/Fellow Councilor*
 Michael A. Nader, *Councilor*
 Mary Jeanne Kallman, *Councilor*
 Carol A. Paronis, *Councilor*
 Annette E. Fleckenstein, *ASPET Council Liaison*
 Christine K. Carrico, *Staff Liaison*

**DIVISION FOR CARDIOVASCULAR
PHARMACOLOGY**

Nancy J. Rusch, *Chair**
 Debra I. Diz, *Chair-Elect***
 Mariana Morris, *Past Chair*
 Debra I. Diz, *Secretary/Treasurer**
 John C. Kermode, *Secretary/Treasurer-Elect*
 Edwin K. Jackson, *Past Secretary/Treasurer*
 William Armstead
 Alan S. Bass
 Ryan M. Fryer
 Steven P. Jones
 Richard Kennedy
 Benedict R. Lucchesi
 Carrie Northcott
 Emel Songu-Mize
 Ann A. Tobin
 Hugo M. Vargas
 Bryan F. Cox, *ASPET Council Liaison*
 Christine K. Carrico, *Staff Liaison*

**DIVISION FOR CLINICAL PHARMACOLOGY,
PHARMACOGENOMICS AND TRANSLATIONAL
MEDICINE**

Brian B. Hoffman, *Chair**
 David A. Flockhart, *Past Chair*
 Darrell Abernethy, *Secretary-Treasurer***
 Ronald N. Hines, *ASPET Council Liaison*
 Christine K. Carrico, *Staff Liaison*

**DIVISION FOR DRUG DISCOVERY, DRUG
DEVELOPMENT AND REGULATORY AFFAIRS**

Ronald L. Dundore, *Chair**
 Gary D. Novack, *Chair-Elect*

Robert W. Caldwell, *Past Chair*
 Michael F. Jarvis, *Secretary/Treasurer*#
 Richard H. Alper, *Secretary/Treasurer-Elect*
 Michael Ahljanian
 Craig Beeson
 Henry R. Besch
 Anindya Bhattacharya
 Jerry Buccafusco
 Marlene L. Cohen
 Curtis Chong
 Timothy Esbenshade
 Robert Leadley
 Tom J. Parry
 Shiladitya Sengupta
 Thomas Stover
 Benjamin R. Yerxa**
 James E. Barrett, *Council Liaison*
 Christine K. Carrico, *Staff Liaison*

DIVISION FOR DRUG METABOLISM

Laurence S. Kaminsky, *Chair**
 Kenneth E. Thummel, *Chair-Elect*
 David S. Riddick, *Past Chair***
 Jeffrey Stevens, *Secretary/Treasurer*
 John Y.L. Chiang, *Secretary/Treasurer-Elect*
 Xinxin Ding, *Past Secretary/Treasurer*
 Emily E. Scott, *Councilor*
 Hollie Swanson, *Councilor*
 David E. Williams, *Councilor*
 Eric F. Johnson, *Editor, DMD, ex officio*
 Ronald N. Hines, *ASPET Council Liaison*
 Christine K. Carrico, *Staff Liaison*

DIVISION FOR MOLECULAR PHARMACOLOGY

Robert A. Nicolas, *Chair*
 Robert H. Tukey, *Chair-Elect*
 Dianne M. Perez, *Past Chair***
 Lee M. Graves, *Secretary/Treasurer*
 Theresa M. Filtz, *Secretary/Treasurer-Elect*
 T.J. Murphy, *Past Secretary/Treasurer*
 Theresa A. Branchek
 Patrick J. Casey
 Kenneth P. Minneman*
 Myron L. Toews
 Elaine Sanders-Bush, *ASPET Council Liaison*
 Christine K. Carrico, *Staff Liaison*

DIVISION FOR NEUROPHARMACOLOGY

David R. Sibley, *Chair***
 P. Jeffrey Conn, *Chair-Elect*



Sandra P. Welch, *Secretary-Treasurer*[#]
 Margarita L. Dubocovich, *Secretary/Treasurer Elect*
 Susan Amara
 Michael Kuhar^{**}
 Christian C. Felder, *Industry Representative*
 Phil Skolnick, *Industry Representative*
 Julie R. Field, *Student Representative*
 R. Benjamin Free, *Fellow Representative*
 Patricia K. Sonsalla, *ASPET Council Liaison*
 Christine K. Carrico, *Staff Liaison*

* Representative to the Scientific Council
 ** Representative to the Program Committee
 # Representative to the Nominating Committee at EB'07

DIVISION FOR PHARMACOLOGY EDUCATION

Jordan Warnick, *Chair*^{*}
 William B. Jeffries, *Past Chair*^{**}
 Jack W. Strandhoy, *Secretary/Treasurer*[#]
 Lynn Crespo
 Jeffrey S. Fedan
 Michelle Kalis
 Raymond Quock
 John Szarek
 Richard Eisenberg, *AMSPC Liaison*
 Gonzalo Torres, *Minorities Committee Liaison*
 Stephanie W. Watts, *Education Committee Liaison*
 Terrence J. Monks, *ASPET Council Liaison*
 Christine K. Carrico, *Staff Liaison*

DIVISION FOR SYSTEMS AND INTEGRATIVE PHARMACOLOGY

R. Clinton Webb, *Chair*^{*}
 George J. Christ, *Past Chair*
 Lori A. Birder, *Secretary/Treasurer*[#]
 Andre Dray, *Past Secretary/Treasurer*^{**}
 Peter Gengo
 Ismail Laher
 Sandeep Samudre
 Harlan E. Shannon
 Robert N. Willette
 Stephen G. Holtzman, *ASPET Council Liaison*
 James Bernstein, *Staff Liaison*

DIVISION FOR TOXICOLOGY

James P. Kehrer, *Chair*^{*}
 Curtis J. Omiecinski, *Chair-Elect*
 Marc W. Fariss, *Past Chair*^{**}
 Alan R. Parrish, *Secretary/Treasurer*[#]
 Lawrence R. Curtis, *Secretary/Treasurer-Elect*
 Jack A. Hinson, *Past Secretary/Treasurer*
 Lynn Wecker, *ASPET Council Liaison*
 Christine K. Carrico, *Staff Liaison*

Have you Joined a Division?

Take full advantage of ASPET Membership by joining a Division!!




You can participate in creating the scientific program for the annual meeting.

You can network with people in your field at the mixers and divisional programming at the annual meeting.



You can participate in running the division and planning its Activities.

You get special notices and newsletters about items and activities of interest in your field.





GUIDELINES FOR THE ORGANIZATION OF AN ASPET CENTENNIAL SYMPOSIUM

The American Society for Pharmacology and Experimental Therapeutics encourages each Division to propose a Centennial Symposium to be presented at the Experimental Biology '08 meeting in San Diego. These Centennial Symposia will be reviewed by the Program Committee at the December 2006 meeting. All other symposia for the 2008 meeting will be reviewed under the normal schedule at the April 2007 meeting.

A Centennial Symposium proposal differs from a regular symposium proposal in that it should have a short introductory talk that places the topic of the symposium in a historical context. This should be followed by 3-4 state-of-the-art scientific talks, of the caliber that one usually expects in a scientific symposium. Finally, there should be a short concluding talk that projects where this research is likely to lead AND the potential payoffs of this research to human health in the next 10 years. For the purposes of the Centennial Symposium only, the normal rule of requiring a speaker to speak for a minimum of 20 minutes in order to qualify for reimbursement will be waived to allow for reimbursement of the introductory and concluding speakers. However, if one of the other speakers is best qualified to present either of these talks, organizers are encouraged to use them for that purpose.

As with all ASPET symposia, organizers are encouraged to consider the following:

- 1) Inclusion of qualified women and minority speakers.
- 2) Inclusion of a "translational" presentation bringing the basic science from "bench to bedside."
- 3) Topics applicable to multiple divisions, with joint sponsorship are encouraged. Organizers are encouraged to contact multiple divisions early in the planning process.

A. Deadline for Submission

For Centennial Symposia ONLY, the proposals are due in the ASPET office by **November 15, 2006**, to allow for processing in preparation for the Program Committee which will occur very shortly thereafter. Divisions may set their own deadlines earlier if they wish to receive and review multiple proposals.

B. Content of Proposal for Symposium

Because of the special nature of these symposia, it is expected that the Division leadership will be actively involved in the organization of these symposia. However, the content of the proposal itself does not differ significantly from the regular symposium proposal. The proposal should present reasons as to why the symposium is desirable and give details on the proposal. The total time assigned for presentations and discussions should not exceed two and one-half hours per symposium. The following points should be addressed in the proposal:

1. Proposed Title
2. Justification of need for an ASPET symposium on the particular topic. There will be a maximum of ten (10) Centennial Symposia, and the justification will be important in both the Division's and the Committee's evaluation. Thus justification should include the timeliness of the topic and



whether a similar symposium has been recently presented at a large scientific meeting at which ASPET members are likely to have been in attendance.

3. Format of the symposium. The format for a Centennial Symposium will include a short introductory talk placing the topic in historical context, 3-4 speakers giving 25-30 minute full-length talks, and a short concluding talk projecting the impact of this research on human health in the next 10 years.
4. Names of proposed speakers, their professional affiliations, title of their presentations, and a one-two sentence synopsis of their topic. Organizers should attempt to identify qualified speakers from multiple institutions so that there is no more than one speaker from a single institution. However, in rare instances where such diversification is not possible, a maximum of two speakers from a single institution may be proposed. Alternate speakers should be proposed and clearly designated as alternates. **Organizers should NOT contact prospective speakers prior to their symposium proposal being reviewed by the Program Committee** as the Committee may suggest changes.
5. Preliminary financial requirements, if any. A total of \$5800 per symposium is available from ASPET to offset the travel costs of the speakers in the symposium. This figure should be kept in mind when planning on foreign speakers (See Section D, below). For the purposes of the Centennial Symposium only, the normal rule of requiring a speaker to speak for a minimum of 20 minutes in order to qualify for reimbursement will be waived to allow for reimbursement of the introductory and concluding speakers. Indicate if there are any plans to secure funding from an alternate source. Funds secured from outside sources may be used to supplement travel reimbursements or to provide for additional foreign speakers, according to the speaker reimbursement guidelines. Neither funds from ASPET nor those secured from outside sources should be used for speaker group lunches or dinners.
6. Organizer and speaker contact information. Include mailing addresses, telephone numbers, and e-mail addresses for the proposed speakers and for the organizer.

C. Review Process

Proposals for **Centennial Symposia ONLY** will be reviewed by the Program Committee in December 2006. Minor revisions may be recommended following that review.

Divisional review may be required prior to November 15, 2006.

D. Financial Assistance from ASPET

No honoraria are provided. Up to \$5800 per symposium is available from ASPET **to support travel for speakers**. Speakers from North America will receive up to a maximum of \$1000 and foreign speakers will receive up to a maximum of \$1500 reimbursement towards travel with receipts. ASPET provides complimentary registration for speakers and moderators in addition to the \$5800 per symposium. Funds are to be used for reimbursing speaker travel and lodging only. They may not be used for speaker group dinners or lunches. Symposium organizers who are not speakers will be given complimentary registration but no travel reimbursement. More detailed speaker reimbursement guidelines are available at http://www.aspet.org/public/meetings/Symp_Spkr_Reimb_Guidel.htm or from the ASPET office (nwhite@aspnet.org).





Bhagaven S. Jandhyala, PhD

On September 23, 2006, a dinner and evening of reminiscing will be held by the University of Houston, College of Pharmacy to recognize the career and accomplishments of Dr. Bhagavan S. Jandhyala, Professor of Pharmacology. Dr. Jandhyala, or “Baggie” as he is known by colleagues and friends, will retire this fall after more than 33 years as a UH faculty member and 32 years as a member of ASPET. Baggie began his career in Pharmacology as a graduate student in the laboratory of the late Dr. Joseph P. Buckley at the University of Pittsburgh, where he earned his PhD in 1966. In 1973, Baggie moved to the

University of Houston, College of Pharmacy where he has taught cardiovascular physiology and pharmacology to many professional and graduate students. His research in cardiovascular pharmacology over the years examined the effects of sodium and volume expansion on the release of endogenous sodium pump inhibitors, the role of free radicals in renal ischemia-reperfusion injury and most recently the role of the kidney in hypertension associated with diabetes/obesity. In honor of Baggie’s contributions to graduate education, a graduate student scholarship endowment is being established and anyone interested in contributing should contact Dr. Mustafa Lokhandwala at the University of Houston (MLokhandwala@uh.edu).

SHARE YOUR NEWS WITH FELLOW ASPET MEMBERS

Send news and photos to sthompson@aspet.org

STAFF NEWS



Miles Rodnan

Miles Rodnan joined the ASPET staff this summer to help staff with several special projects. Collaborating with the Membership department, Miles played a large role in updating our membership database this summer. He also worked with the Journals department to help correct bad links on our Journals websites. Miles also did some research work for *Molecular Interventions*. Miles will be starting his senior year at Richard

Montgomery High School this year. He is on the Golf Team and also enjoys participating in the Film Club at school. The ASPET staff threw a “Goodbye” party for Miles at the end of August, where he was presented with a cake and back to school supplies.



ASPET WOULD LIKE TO WELCOME THE FOLLOWING NEW MEMBERS:

Regular Members

Adcock, Ian, NHLI, Imperial College London, Airways Disease Section
Akk, Gustav, Washington University St. Louis, Dept of Anesthesiology
Albensi, Ben, St. Boniface Research Center, Division of Neurodegenerative Disorders
Ding, Jian, Shanghai Institute of Materia Medica, Division Antitumor Pharmacology
Huizinga, Jan, McMaster University, Dept of Medicine & Biomedical Sciences
Hussain, Azher, Wyeth Research
Iaccarino, Guido, Federico II University, Dept of Internal Medicine
Kobayashi, Kaoru, Chiba University, Dept of Pharmacology & Toxicology
Lee, May, Iconix Pharmaceuticals, Dept of Drug Informatics
Moniri, Nader, Mercer Univ College of Pharm & Hlth Sci, Dept of Pharm Sciences
Peti, Wolfgang, Brown University, Dept of Molecular Pharmacology, Physiology
Pradhan, Leena, Harvard Institutes of Medicine, Beth Israel Deaconess Medical Center
Strom, David, Des Moines University, Dept of Physiology & Pharmacology
Yu, XiYong, Guangdong Provincial People's Hospital, Research Ctr for Med Sciences

Affiliate Members

Davis, Jillian, Hampton University School of Pharmacy, Kittrell Hall
Hickman, Lana, Schering-Plough
Reynolds, Derek, ReYTEK Limited

Graduate Student Members

Advani, Tushar, University of Texas HSC, Dept of Pharmacology
Aggarwal, Nitin, Medical College of Wisconsin, Dept of Pharmacology & Toxicology
Bair, Angela, University of Illinois, Dept of Pharmacology
Barrera, Jose, Univ of Texas Southwestern Medical Ctr, Dept of Pharmacology
Barrett, Kelly, University of Illinois, Dept of Pharmacology
Becker, Ginger, University of Texas HSC, Dept of Pharmacology
Bolduc, Timothy, University of Utah, Dept of Pharmacology & Toxicology
Brignac, Lauren, Louisiana State Univ HSC, Dept of Pharmacology & Therapeutics
Bryant, Vashti, Univ of Texas Medical Branch, Dept of Pharmacology & Toxicology
Bush, Cristina, Emory University, Dept of Pharmacology
Caces, Donne, SUNY Stony Brook, Dept of Pharmacology
Cadwallader, Amy, University of Utah, Dept of Pharmacology & Toxicology
Campbell, Rowena, University of Arizona, Dept of Medical Pharmacology
Cardenas, Jessica, Univ of Texas Southwestern Medical Ctr, Dept of Pharmacology
Carmon, Kendra, University of Texas HSC Medical School, Dept of Pharmacology
Carrier, Raeann, Ohio State University, Dept of Pharmacology
Chawengsub, Yuttana, Medical College of Wisconsin, Dept of Pharm & Toxicology
Chen, Yukun, Texas Tech Univ, Dept of Pharmacology & Neuroscience
Chen, Qingmin, University of Arizona, Dept of Medical Pharmacology
Chen, Mark, Univ of Texas Southwestern Medical Ctr, Dept of Pharmacology
Cheng, Hanyin, University of Texas HSC Medical School, Dept of Pharmacology
Chow, Christina, University of Illinois, Dept of Pharmacology
Corrales-Higuera, Alexandra, SUNY Stony Brook, Dept of Cell and Molecular Pharmacology



NEW MEMBERS

Curtis, Jeremy, University of Texas HSC, Dept of Pharmacology
Deering, Cassandra, University of Utah, Dept of Pharmacology & Toxicology
Desai, Brinda, Rush University Medical Center, Dept of Pharmacology
Dodrill, Michael, West Virginia University, Dept of Industrial Hygiene
Dul, Barbara, UMDNJ-RWJMS, Dept Cellular and Molecular Pharmacology
Duran, Emmanuel, Texas Tech University HSC, Dept of Biochemistry
Dwyer, Gena, Oregon State University, Dept of Pharmaceutical Sciences
Endsley, Michael, Medical College of Wisconsin, Dept of Pharmacology
Erdman, Nathan, Univ of Nebraska Med Ctr, Dept of Pharmacology & Exp Neuroscience
Fahmy, Baher, Louisiana State Univ HSC Sch of Med, Dept of Pharm & Exp Therapeutics
Faiza, Baameur, University of Texas HSC Medical School, Dept of Pharmacology
Fan, Fenghui, Univ of Texas Medical Branch, Dept of Pharmacology & Toxicology
Farnsworth, Sarah, University of Utah HSC, Dept of Neuroscience
Feigin, Michael, SUNY Stony Brook, Dept of Molecular & Cellular Pharmacology
Garza, Jacob, University of Texas HSC, Dept of Pharmacology
Gaspar, Renee, University of Utah, Dept of Neuroscience
Gottimukkala, Vamsi, Rush University Medical Center, Dept of Pharmacology
Graves, Joseph, Howard University, Dept of Biology
Hamouda, Ayman, Texas Tech Univ HSC, Dept of Pharmacology
Harley, Jill, Emory University, Dept of Pharmacology
Henion, Frederick, University of Utah, Dept of Pharmacology
Hillis, Amanda, University of Texas HSC, Dept of Pharmacology
Hubbard, Kate, Emory University, Dept of Pharmacology
Hurst, Jillian, University of Georgia, Dept of Pharmacy
Hutchinson, Kirk, Louisiana State University HSC, Dept of Pharmacology
Ide, Lucienne, Emory University, Dept of Pharmacology
Irier, Hasan, Emory University, Dept of Pharmacology
Jackson, Chad, Emory University, Dept of Pharmacology
Ji, Zhenyu, University of Texas Medical Branch, Dept of Pharmacology & Toxicology
Kadiu, Irena, Univ of Nebraska Med Ctr, Dept of Pharmacology & Exp Neuroscience
Kanske, Jason, University of Texas HSC, Dept of Pharmacology
Katz, Paige, Louisiana State University HSC, Dept of Pharmacology & Physiology
Khasawneh, Fadi, University of Illinois, Dept of Pharmacology
Kilpatrick, Shannan, University of Texas HSC Medical School, Dept of Pharmacology
Kirkland, Porche, Emory University, Yerkes Nat'l Primate Rsch Center
Kline, Erik, Emory University, Dept of Molecular & Systems Pharmacology
Kraft, Stephanie, Univ of Nebraska Med Ctr, Dept of Pharmacology & Exp Neuroscience
Kuhr, Frank, University of Illinois, Dept of Pharmacology
Kwiatek, Angela, University of Illinois, Dept of Pharmacology
Lanfranco, Maria, Univ of Texas Medical Branch, Dept of Pharmacology & Toxicology
Larsen, Brandon, Medical College of Wisconsin, Cardiovascular Center
Lee, Sarah, Emory University, Dept of Molecular & Systems Pharmacology
Lewis, Karen, Univ of Texas Southwestern Medical Ctr, Dept of Pharmacology
Lindstrom, Beatriz, University of Arizona, Dept of Medical Pharmacology
Love, Damon, SUNY Stony Brook, Dept of Pharmacology
Luke, Toni, Univ of Nebraska Med Center, Dept of Pharmacology & Exp Neuroscience
McCoy, Kelly, Emory University, Dept of Molecular & Systems Pharmacology
McLaughlin, Richard, Univ of Texas Southwestern Medical Ctr, Dept of Pharmacology
Melton, Alexis, Univ of Texas Southwestern Medical Ctr, Dept of Pharmacology
Mitrano, Darlene, Emory University, Dept of Pharmacology
Moore, Chad, University of Utah, Dept of Pharmacology & Toxicology



NEW MEMBERS

Nguyen, Tom, SUNY Stony Brook, Dept of Pharmacology
Paavola, Kevin, Emory University, Dept of Pharmacology
Phatarpekar, Prasad, University of Texas HSC, Dept of Cell & Regulatory Biology
Piggott, Leslie, University of Texas HSC, Dept of Integrative Biology & Pharmacology
Ponnoth, Dovenia, West Virginia University, Dept of Physiology & Pharmacology
Potts, Patrick, Univ of Texas Southwestern Medical Ctr, Dept of Cell Regulation
Pruett, Shondra, Univ of Texas Southwestern Medical Ctr, Dept of Pharmacology
Punati, Ashok, Rush University Medical Center, Dept of Pharmacology
Qin, Jianbing, Creighton University, Dept of Pharmacology
Rajput, Kartic, Louisiana State Univ HSC, Dept of Pharmacology & Exp Therapeutics
Ramos, Fresnida, University of Texas HSC, Dept of Pharmacology
Riedy, Matthew, University of Utah, Dept of Pharmacology & Toxicology
Rodvelt, Kelli, University of Missouri, Dept of Psychological Sciences
Roy, Lynn, Univ of Nebraska Med Center, Dept of Pharmacology & Exp Neuroscience
Sabnis, Ashwini, University of Utah, Dept of Pharmacology & Toxicology
Sadana, Pradodh, University of Tennessee, Dept of Pharmacology
Sanghvi, Mitesh, Texas Tech Univ HSC, Dept of Pharmacology & Neuroscience
Sasman, Amy, Medical College of Wisconsin, Dept of Pharmacology
Sawey, Eric, SUNY Stony Brook, Dept of Pharmacology
Schmidt, Kady, Univ of Texas Medical Branch, Dept of Pharmacology & Toxicology
Shank, Erik, Univ of Texas Medical Branch, Dept of Pharmacology & Toxicology
Shanmugarajah, Dakshine, University of Texas HSC, Dept of Pharmacology
Shenouda, Sylvia, Louisiana State Univ HSC, Dept of Pharm & Exp Therapeutics
Shi, Leyu, Medical College of Wisconsin, Dept of Pharmacology
Shiner, Thomas, Texas Tech Univ HSC, Dept of Pharmacology & Neuroscience
Song, Yan, SUNY Stony Brook, Dept of Pharmacology
Stewart, Jennifer, University of Texas HSC, Dept of Pharmacology
Stiles, Linsey, Tufts Univ School of Med, Dept of Pharmacology & Exp Therapeutics
Strong, Tori, University of Texas Medical Branch, Dept of Pharmacology & Toxicology
Sun, Haiping, University of Arizona, Dept of Pharmacology
Taylor, Tonya, Emory University, Dept of Pharmacology
Thomas, Shala, Emory University, Dept of Pharmacology
Titus, Kerry, Emory University, Dept of Pharmacology
Wan, Zhou, University of Arizona, Dept of Pharmacology
Wang, Lixin, University of Texas, HSC, Dept of Pharmacology
Watkins, Jermel, SUNY Stony Brook, Dept of Pharmacology
Whitney, Nicholas, Univ of Nebraska Med Ctr, Dept of Pharmacology & Exp Neuroscience
Willert, Erin, Univ of Texas Southwestern Medical Ctr, Dept of Pharmacology
Williams, Dumaine, SUNY Stony Brook, Dept of Pharmacology
Williams, Holly, Emory University, Dept of Pharmacology
Wrage, Philip, Univ of Texas Southwestern Medical Ctr, Dept of Pharmacology
Xia, Yan, University of Texas Medical Branch, Dept of Pharmacology & Toxicology
Yang, Wenqi, Medical College of Wisconsin, Dept of Pharmacology
Yi, Fan, Virginia Commonwealth Univ, Dept of Pharmacology
Yondola, Mark, SUNY Stony Brook, Dept of Pharmacology

[Undergraduate Student Members](#)

Alewine, Rachel, Univ of Kansas Med Ctr, Dept of Dept Pharmacology & Toxicology
Allen, Moniesha, USUHS, Dept of Pharmacology
Blackwater, Thomasina, Univ of Arizona, Undergraduate Biology Research Program



NEW MEMBERS

Byrd, Katrina, USUHS, Dept of Pharmacology
Chan, Kara, University of Texas HSC, Dept of Pharmacology
Chapman, John, University of Arizona, Undergraduate Biology Research Program
Chen, Shepin, University of Arizona, Undergraduate Biology Research Program
Crawford, Jeffrey, Northwestern Univ, Dept of Molecular Pharmacology & Biological Chemistry
Desai, Meeta, USUHS, Dept of Pharmacology
English, Danielle, Monmouth College, Dept of Biochemistry
Faver, John, University of Arkansas for Medical Sciences, Dept of Chemistry
France, Adrian, University of Texas HSC, Dept of Biology
George, Thresiamma, University of Texas, Dept of Neuroscience
Hatley, Stephen, University of Texas HSC, Dept of Pharmacology
Holthoff, Joseph, University of Arkansas for Medical Sciences, Dept of Pharmacology
Jackson, Kari, Vanderbilt University, Dept of Pharmacology
Jiang, Rosie, Vanderbilt University, Dept of Pharmacology
Kaushal, Pankaj, USUHS, Dept of Pharmacology
Kirry, Adam, Ohio State University, Dept of Pharmacology
Komura, Akiko, University of Colorado, Dept of Pharmacology
Lantz, Susan, University of Central Arkansas, Dept of Pharmacology
LaVallie, Nicole, Northwestern University, Chemical Biology Center
Lee, Kelvin, University of Texas Medical Branch, Dept of Pharmacology & Toxicology
Lindsey, Christina, University of Central Oklahoma, Dept of Chemistry of Biology
Lopez, Melissa, University of Colorado, Dept of Pharmacology
Mehta, Mitali, University of Michigan, Dept of Pharmacology
Melton, Ashley, Univ of Kansas Medical Center, Dept of Pharmacology & Toxicology
Meredith, Keven, University of Arkansas for Medical Sciences, Dept of Pharmacology
Merten, Kevyn, University of Louisville, Dept of Pharmacology & Toxicology
Murphy, Daniel, Northwestern University, Dept of Molecular Pharmacology & Biological Chemistry
Neeley, Om, University of Texas HSC, Dept of Pharmacology
Ooms, Laura, Northwestern University, Dept of Molecular Pharmacology & Biological Chemistry
Ota, Shodai, University of Michigan, Dept of Biochemistry
Pennington, Abby, Oral Roberts University, Dept of Pharmacology
Petzold, Jacquelyn, Univ of Kansas Med Center, Dept of Pharmacology & Toxicology
Pritts, Casey, University of Pittsburgh, Dept of Pharmacology
Reimer, Graham, Univ of Kansas Medical Center, Dept of Pharmacology & Toxicology
Ruiz, Angelina, USUHS, Dept of Pharmacology
Sanders, Paige, McNeese State University, Dept of Chemistry/Biochemistry
Skillin, Katie, Univ of Kansas Medical Center, Dept of Pharmacology & Toxicology
Stanley, Illana, USUHS, Dept of Pharmacology
Tabis, Lauren, University of Arizona, Undergraduate Biology Research Program
Tchoua, Phoebe, University of Colorado HSC, Dept of Pharmacology
Twynier, Channing, Belmont University, Dept of Biochemistry
Vogel, Laura, University of Arizona, Undergraduate Biology Research Program
Vyas, Jay, University of Arkansas for Medical Sciences, Dept of Pharmacology
Wasmuth, Elizabeth, University of Colorado HSC, Dept of Pharmacology
Wilgenbusch, Sara, Vanderbilt University Medical Center, Dept of Pharmacology
Yoon, Dan, University of Michigan Medical School, Dept of Pharmacology





Deepak Bose M.D., Ph.D.
August 24, 1941 – August 8, 2006

It is with great sadness that we announce the sudden but peaceful passing of Dr. Deepak Bose at the age of 64.

Deepak was born in India. He obtained his degree in Medicine from the Mahatma Gandhi Memorial Medical College in 1963, earning several gold medals and pursuing subspecialization in Pharmacology. He immigrated to Winnipeg along with his wife and daughter in 1968, where he completed his PhD in Pharmacology and Therapeutics under the supervision of Dr. Ian Innes.

He had a long and distinguished career as a Professor of Pharmacology and Therapeutics in the Faculty of Medicine. In recent years, he served as Associate Head of the Department. Deepak was Professor, also, in the Department of Anesthesia, where he made substantial academic and clinical contributions.

His research interests focused on cardiac physiology, pharmacology and pathology. Areas of extensive publication include the description of the mechanism of action of synthetic and biologically derived inotropic agent, regulation of cardiac excitation and ionic regulation of cardiac mechanical and electrical activity, and cardiac dysfunction in septic shock. These studies utilized a range of methods from integrative whole animal preparations to the electrophysiology of single cells. Dr. Bose established an anesthesia screening program for malignant hyperthermia, one of only a few in North America.

Deepak maintained memberships in many scientific societies. His academic accomplishments were recognized by continuing demands on his time by national and international scientific organizations.

In addition to excellence in research, Dr. Bose was heavily involved in teaching throughout his career. With the introduction of the new medical curriculum, his training in both basic and clinical sciences was of great value in teaching and in curriculum design in the undergraduate program. He chaired the Committee of Evaluation for a number of years and was responsible for the use of information technology for teaching medical students. He was instrumental in implementing formative evaluation of pre-clerkship medical students. For years he worked tirelessly in remedial studies with students in academic difficulty. He developed computer-assisted medical student performance tracking and enhancement. Furthermore, Deepak's extensive contributions to postgraduate education in the Faculty of Medicine and to the Faculty of Pharmacy were regularly recognized.

Deepak was repeatedly nominated for the Outstanding Teaching Award in the Faculty of Medicine and was the recipient of the University's Dr. and Mrs. Saunderson Award for Excellence in Teaching in 1991. To quote one of his students: "He was incredibly intelligent, gentle, respectful, as well as mischievous; and he believed in the necessity of not only teaching, but mentoring. I can't help but wonder if a majority of the person I am today is because of him."

Deepak will be remembered as a devoted family man. He was a pillar of support and voice of reason to his large extended family and friends. He derived great joy from his grandchildren to whom he imparted a love of learning from a very early age. His other loves included music, fine cuisine, computers and electronic devices in general. He took delight in playing practical jokes on his family. He will be deeply missed by his wife of 40 years, Ratna; children, Reeni (Sushane) and Shouren; grandchildren, Rayan, Mona and Neel; brothers, Anjan (Roopa) and Ranjan (Ratna).

Prepared by Frank S. LaBella from University of Manitoba





Grant Robert Wilkinson, Ph.D., D.Sc. August 27, 1941 – June 13, 2006

In the death of Grant R. Wilkinson on June 13, 2006, pharmacology and its sister discipline clinical pharmacology lost an important scientist and contributor, known internationally for his extensive research into factors contributing to inter-individual determinants of drug responsiveness.

Born into a working class family in Derby, England, during the Second World War, Grant was molded by the circumstances, attitudes and mores of this period. Critically, entry into the academically selective grammar school system eventually led, to the surprise of some of his teachers, especially because he had considered a career as a professional soldier in the British Army, to acceptance at the University of Manchester. Grant thrived in this academic atmosphere and was selected into the Honors program in Pharmacy. This provided an introduction to research that subsequently led to his becoming a graduate student of Arnold H. (Joe) Beckett at the Chelsea College of Science and Technology, University of London. His Ph.D. thesis focused on the effect of urinary pH on the excretion of basic amines, including the ephedrines. Circumstances required him to quickly become an independent researcher, and his immediate insertion into laboratory research taught Grant the importance of choosing productive avenues of research, attention to detail, the need for clear communication in both written and oral presentations, an emerging interest in human clinical research, and the need to be an effective salesman of important ideas.

After receiving his Ph.D. degree in 1966, Grant became part of the “brain drain” of young scientists who wanted to get their “Been to America (BTA) degree.” Although the area of drug addiction *per se* was of little specific interest, Grant spent an enjoyable and rewarding two years in Eddie Leong Way’s laboratory at the University of California at San Francisco, broadening his interest in bioanalysis and drug disposition and picking up his initial credentials as a pharmacologist. At the same time, he benefited from a close relationship with Sid Riegelman’s group in the School of Pharmacy, who were beginning to develop modern pharmacokinetics and its applications.

A decision to remain in the USA resulted in Grant moving to the University of Kentucky as an Assistant Professor of Materia Medica. The clinical pharmacy movement was just beginning, and Kentucky was a leading center; however, Grant soon recognized that his *métier* was research and, in particular, that in humans. Accordingly, in 1971 he moved to Vanderbilt University where he advanced through the academic ranks and remained for the next 35 years. The early 1970s were halcyon years under the nurturing attention of John Oates in the Division of Clinical Pharmacology and in collaboration with the group of young, very bright and ambitious clinician-investigators who had been recruited and drawn to Nashville. Initially Grant was responsible for establishing what was probably the first dedicated therapeutic drug monitoring laboratory and consultative service within the United States, but it was the clinical research area which provided him the most satisfaction.

Along with David Shand, Grant published a seminal paper describing the “well-stirred” model of hepatic elimination and the concept of “intrinsic clearance.” Stated simply, this provided a practical and ready tool to reliably understand and predict changes in the pharmacokinetics of a drug resulting from alterations in physiological determinants, from the presence of disease or from the co-administration of other drugs and other environmental factors, according to the route of administration. The model also provided an approach for quantitatively extrapolating *in vitro* metabolism to the *in vivo* situation that is now widely used by the pharmaceutical industry. A “citation classic,” this work is still extensively cited 30 years later. Insights provided by the model then led Grant to begin to systematically investigate how liver disease of various types and severity affected disposition according to the drug’s “intrinsic clearance” and involved metabolic pathways. Similarly, Grant was a pioneer in determining how aging affected drug metabolism and pharmacokinetics.

In the late 1970s, the Vanderbilt group discovered what is now known as the *CYP2C19* genetic polymorphism. Using classical genetic approaches based on phenotypic characteristics, Grant contributed to the understanding of this polymorphism and was able to finally, through collaborative studies with Joyce Goldstein, determine the major molecular mechanisms associated with the “poor metabolizer” phenotype. This work had several additional consequences; first it stimulated Grant’s broader interests in pharmacogenetics; second it led to an appreciation of racial/ethnic differences in drug metabolism; and finally, it showed the value of the “*in vivo*” probe approach for studying variability in drug



OBITUARY

metabolizing ability in individuals. These themes were interwoven over the next two decades of Grant's career as he investigated other factors contributing to differences in CYP2B6, CYP2D6, CYP2E1 and CYP3A activities, among others.

Presciently, in the early 1990s Grant turned his attention to the area of drug transport, at a time before this was recognized as being important in drug disposition. Along with Richard Kim, at that time a post-doctoral fellow, he found that HIV protease inhibitors were found to be substrates of P-glycoprotein and that this important protein exhibits genetic polymorphisms – significant initial contributions that established the Vanderbilt group as leaders in the transporter area. Finally and largely unheralded, was Grant's idea of developing a DNA bank for all HIV infected patients enrolled on NIAID sponsored trials – a resource of tremendous future potential for studying the importance of genetics in antiretroviral drug responsiveness.

Grant had an ability to identify important areas at the leading edge of clinical pharmacology before most other investigators. Accordingly, he developed many new concepts and ideas that pushed forward the frontiers of knowledge in the area of human drug metabolism and disposition. The value of his scientific contributions is attested to by the fact that his publications are among the most widely cited in pharmacology over the past 25 years. Additionally, he received several honors including an NIH MERIT award, the 1996 Rawls-Palmer in Medicine Award from the American Society of Pharmacology and Experimental Therapeutics, the 2000 Research Achievement Award in Pharmacokinetics, Pharmacodynamics and Drug Metabolism of the American Association of Pharmaceutical Scientists, many distinguished lectureships awards from various universities, and membership in the prestigious Athenaeum Club, London. Grant served on numerous editorial boards over his career and was an Associate Editor to the *Journal of Pharmacology and Experimental Therapeutics* (1992-1997) and *Clinical Pharmacology and Therapeutics* (2002-present).

In addition to his academic achievements, Grant will be greatly missed as a loyal and generous friend and a thoughtful counselor whose advice was widely sought on academic matters. He bore his final illness with his characteristic courage, dignity and even style. It is hard to imagine Clinical Pharmacology at Vanderbilt without the characteristic tap tap tap of Grant's shoes in the hallways. We have lost a giant who gave so much to the field of clinical pharmacology that is hard not to feel we have been cheated out of more through his loss. An era has ended.

Prepared by Alastair Wood from Vanderbilt University.

IN SYMPATHY

ASPET notes with sympathy the passing of the following members:

William O. Berndt
Deepak Bose
W. Marvin Davis
Robert D. Ford
Lloyd J. Forman
Eva K. Killam
Robert G. Lamb
Winston S. Marshall
Alan R. P. Paterson
J. Palmer Saunders
Joseph J. Schildkraut
Jaroslav J. Vostal
James W. West
Grant R. Wilkinson
Martin M. Winbury



ASPET SURVEY RESULTS

ASPET would like to thank all our members who took part in the ASPET Members Survey this summer. 982 members participated in the anonymous survey and offered their opinions, criticisms, and suggestions. The survey was designed to examine all areas of Society membership and participation. Consisting of 35 multiple choice questions and 3 open-ended comment questions, the survey asked members to consider general membership benefits, ASPET journals, the EB/ASPET Annual meeting, and ASPET's public policy efforts. A summary of the results are outlined below.

General Membership and Benefits:

The majority of ASPET members feel that ASPET is successfully meeting their professional needs. Most respondents belong to one or more ASPET divisions and are aware that Society activities can be directed through membership in the divisions. The survey also showed a strong positive opinion of the membership benefits we offer. More than half of all survey respondents find all our benefits useful to their work in pharmacology.

ASPET Member Benefits	Very Useful	Moderately Useful	Not Useful
Reduced page charges to publish in ASPET Journals	41%	38%	21%
Free online access to ASPET Journals	74%	20%	5%
Reduced registration fees for ASPET meetings	58%	33%	9%
Travel Awards and Best Abstract Awards	37%	30%	33%
Free subscription to Molecular Interventions	52%	37%	12%
Reduced subscription rates for ASPET print Journals	25%	35%	40%
Free listing in the FASEB Directory	48%	41%	11%
Free Membership in the ASPET divisions	55%	38%	7%
Access to Journal back issues	66%	26%	8%
Public affairs advocacy for research funding and science policy	45%	41%	14%

ASPET Journals:

This section of the survey measured how members are making use of the ASPET journals. A majority of members do read the ASPET journals and most use only the Online versions of the journals, which are free to all members. However, 70% of survey respondents said that they do not make use of the Electronic Table of Contents Alert Service (eTOC). A majority of survey respondents also stated they publish their manuscripts in ASPET journals.

Molecular Interventions:

Molecular Interventions was launched with the mission to reach out to the ASPET community and to explore the breadth of pharmacological science as a discipline and profession. According to our survey, 70% of members read *Molecular Interventions* on a regular basis. Of those who read *Molecular Interventions*, mostly everyone had very positive remarks about the journal. *Molecular Interventions* is widely shared with students and colleagues and over 50% of readers have recommended that their library subscribe to the journal. Most of the features in *Molecular Interventions* are read regularly, showing that the value of this publication is considered quite high among members.

Features in <i>MI</i>	Always	Sometimes	Never
Reflections (Historical & Cultural Perspectives)	42%	55%	3%
Speaking of Pharmacology (Professional Views of Pharmacology)	43%	53%	4%
Crosstalk (Interviews)	29%	64%	7%
Nascent Transcripts (Hot Paper Blurbs)	39%	56%	5%



ASPET SURVEY RESULTS

Viewpoint (Shorter Review of Research Trends)	47%	51%	2%
Review Articles	52%	47%	1%
Beyond the Bench (Book/Movie Reviews)	18%	57%	25%
Net Results (Sites of Interest on the World Wide Web)	19%	59%	22%
On Deck (Upcoming Meetings)	23%	58%	19%
Career Opportunities	16%	42%	43%
Outliers (Cartoon)	39%	47%	13%

EB/ASPET Annual Meeting:

Survey responses regarding attendance at the EB/ASPET Annual Meeting were split, with only about half attending the meeting regularly. The members who do attend seem to be happy with the overall programming of the meeting and accept that the meeting provides the professional development opportunities they seek. Attendees find that the most important aspects of the meeting are the Symposia, Networking Opportunities, and Lectures.

Public Policy:

ASPET's public affairs mission and objectives are to respond as priority to issues that are of unique interest to pharmacologists and to give priority to those pharmacology related issues that the Society might be able to favorably impact. 52% of you feel that ASPET does adequately advocate for your profession. The other 48% are uncertain about this. However an overwhelming majority of members do feel that it is important that policy makers, consumers, and the public view ASPET as a primary source of highly valued, objective, and credible scientific information.

We asked members about specific efforts that ASPET supports and to what degree you support them. For the most part, ASPET's advocacy efforts are strongly supported by members.

Advocacy Efforts	Strongly Support these efforts	Support these efforts with some reservation	Oppose ASPET support of this issue
ASPET has supported public education and advocacy efforts to defend the teaching and science of evolutionary theory against movements such as Intelligent Design.	81%	13%	6%
ASPET has supported public education and advocacy efforts to enhance federal funding for human embryonic stem cell research	78%	18%	4%
ASPET advocates for training of integrative, whole organ pharmacology	87%	12%	1%
ASPET advocates for increased support for botanical medicine and reform of dietary supplement regulations.	67%	30%	3%
ASPET advocates for NIH funding	91%	8%	1%



ASPET SURVEY RESULTS

Open-ended Questions:

We asked three open-ended questions at the end of the survey. Again we had a very high response to these questions.

What important issues do you feel ASPET should concentrate its advocacy efforts?

Comments to this question offered a variety of suggestions. Common suggestions were about focusing on NIH funding, concentrating efforts on Federal funding, defending the use of animals in research, supporting Stem Cell Research, and educating the public about Science and Pharmacology.

What kinds of member benefits would make the Society more attractive to young scientists and/or industry scientists?

Comments to this question could be split into five main groups:

Journals – suggestions focused on free access to journals being a good benefit to attract members.

Meetings – we had a large number of respondents suggesting that membership attraction should be concentrated in the meetings. Comments ranged from the financial side (“making registration cheaper”) to the more program-oriented side (“getting these groups more involved in presenting at meetings”). There were also a few comments suggesting that ASPET needs smaller and more focused meetings.

Grants/Awards/Funding – there were many comments stating that awards and funding are the best way to attract young scientists.

Training/Mentoring/Networking/Career Opportunities – the majority of comments fell into this category. Many comments suggested that mentoring opportunities and programs need to be in place for younger scientists, as well as networking opportunities with our regular members. Overall, these comments recommend that current members need to be more involved in recruiting, training, and mentoring young scientists.

Membership Costs – some respondents felt that we should reduce membership fees for young scientists and industry scientists as a way to attract them to the society.

Please tell us any additional comments or suggestions you have for ASPET.

As this question was quite broad, we had a variety of answers ranging from suggestions about how to attract more members to comments about how ASPET is handling the journals and meetings. We had a large amount of very positive comments stating that members were very happy with ASPET’s current benefits, policies, and activities. We also had comments suggesting that members would like to get more involved in attending the meetings but that time constraints and limited funds were a problem. We also had quite a few retired members asking for more involvement in the Society and more updates on ASPET news and obituaries. There were some specific comments about what members would like to see in our journals, such as a “section on biotechnology,” etc.

Overall, we have found the survey results very helpful in reviewing the work of ASPET. Our main goal is to attract members to our Society and keep members informed and satisfied with the work of ASPET, providing members with the resources they need to meet their professional goals. This survey provided us some insight into what members really think and we will be working to incorporate your ideas and suggestions as ASPET continues to grow and serve your pharmacological needs.



THE GREAT LAKES CHAPTER

The **Great Lakes Chapter of ASPET** held its annual meeting on June 9, 2006, at University of Illinois at Chicago, Chicago, IL. The meeting was attended by over 80 pharmacologists from the greater Chicago area and the surrounding states of Wisconsin, Indiana and Michigan. This year's symposium was focused on the theme "Cancer: Emerging Targets and Therapies." The symposium featured an outstanding panel of speakers including Jacqueline Bromberg, clinician at Memorial Sloan-Kettering Cancer Center, New York, who discussed her work on "Inhibition of JAK and STAT proteins in tumor malignancy formation"; Steve Elmore, research scientist from Abbott Laboratories Cancer Therapeutics, who discussed his work on "Small molecule inhibitors of Bcl-2 family proteins: a novel approach to cancer therapy"; and Don Davidson, research scientist, from Abbott Laboratories Cancer Therapeutics, who discussed "Apoptosis of



GLC-ASPET President Elizabeth (Bess) Everitt opens the 19th Annual Scientific Meeting for the chapter on 09 June 2006, at the University of Illinois at Chicago campus.

endothelial and tumor cells by Kringle 5 and a thrombospondin-mimetic inhibits tumor growth." The keynote address was presented by Michael Sporn, noted clinician from Dartmouth Medical School in New Hampshire, and prominent cancer biologist with over 35 years of Cancer biology and therapeutics experience at the NIH Cancer. Michael's talk was entitled "New synthetic triterpenoids and rexinoids: multifunctional agents with many potential clinical applications, both for prevention and treatment of disease." Along with this outstanding symposium and keynote address, the meeting featured a career workshop, vendor exhibits, a poster session and the annual student and postdoctoral research competitions.



Keynote speaker Michael Sporn, from Dartmouth Medical College, gives his lecture on "New synthetic triterpenoids and rexinoids: multifunctional agents with many potential clinical applications, both for prevention and treatment of disease."

Winners of the Research Competitions were:

Graduate Student Awards

- 1st Syed Ahmed, University of Michigan Medical School
- 1st Brinda Desai, Rush University
- 2nd Fadi Khasawneh, University of Illinois at Chicago
- 3rd Marija Milenkovic, University of Illinois at Chicago

Postdoctoral Fellow Awards

- 1st Francis Edwin, Loyola University
- 2nd Rajesh Kumar, University of Illinois at Chicago



More Pictures from the 19th Annual GLC-ASPET Scientific Meeting
June 9th 2006



Executive Committee GLC-ASPET Vice-President, Karie Scrogin, from Loyola University (right), and Vicki Sears and Peter Lamar, both from Midwestern University (left) staff the meeting registration. The 19th Annual GLC Meeting marked the first time online-registration and abstract submission had been offered to attendees for a regional ASPET meeting.




GLC-ASPET Scientific Meeting attendees enjoy a mid-afternoon break of chatting, networking, and refreshments between the Symposium and the Keynote address.



GLC-ASPET Executive committee members attend a dinner after the Annual Scientific Meeting. In the foreground are (left) President, Elizabeth (Bess) Everitt, from Baxter Healthcare, and (right) Councilor, Karen Snapp, from University of Illinois at Chicago. In the background are Symposium speakers Don Davidson (behind Dr. Everitt) and Steve Elmore (green shirt), both from Abbott Laboratories.

The GLC-ASPET Executive Committee gratefully acknowledges support for the meeting from: ASPET; Abbott Laboratories; Chirality LLC; Indiana University School of Medicine - Northwest; Loyola University School of Medicine, Department of Pharmacology; Medical College of Wisconsin, Department of Pharmacology; Midwestern University; Northwestern University, Rosalind Franklin University, Department of Cellular and Molecular Pharmacology; Rush Medical College, Department of Pharmacology; University of Illinois at Chicago College of Medicine, Department of Pharmacology. In addition, we would like to thank the following vendor exhibitors for their support: ADInstruments, Inc.; Clever Sys, Inc.; EMD Biosciences; Kimble Glass, Inc.; Mallinckrodt Baker; W. Nuhsbaum, Inc.





Mid-Atlantic Pharmacology Society Meeting

New Advances in Pain Research
 October 27, 2006

Scanticon Conference Center
 1210 First Avenue, King of Prussia, Pennsylvania

Meeting Program

- 7:45 am** **Registration, Continental Breakfast & Poster Set-up**
- 8:30 am** **Welcome**
 Ronald J. Tallarida, *President, Mid-Atlantic Pharmacology Society*
Introduction to the Program
 Jim Barrett (*Adolor*) and Mike Williams (*Cephalon*)
- 8:45 am** **Keynote Lecture: Challenge in Pain Research**
 Clifford Woolf, *Massachusetts General Hospital*
- 9:45 am** **Progress in Opioid Targeted Analgesics**
 Rolf Windh, *Adolor*
- 10:30 am** **Break (coffee)**
- 11:00 am** **TRPV1 – Current Advances**
 Prisca Honore, *Abbott*
- 11:45 am** **MAPS Awards: G B Koelle Award**
- 12:15 pm** **Lunch & Poster Presentations**
- 2:00 pm** **Pain & Pruritis: The Pharmacological Overlap**
 Alan Cowan, *Temple University*
- 2:45 pm** **Assessing Pain Models**
 Michael R. Brandt, *Johnson & Johnson*
- 3:30 pm** **Break**
- 3:45 pm** **Poster Awards**
- 4:00 pm** **Reception & Refreshments**

For meeting information, contact: Jeanne Coughlin (215-707-5227), jeanne.coughlin@temple.edu or visit our website at http://www.aspet.org/public/chapters/maps_chapter.htm



27th Annual Meeting of the Southeastern Pharmacology Society

The University of Mississippi

Department of Pharmacology & National Center for Natural Products Research

November 5-7, 2006

Meeting Program

Sunday, November 5th

6:00-8:00PM Reception – Memory House

Monday November 6th

Emerging Therapeutics in Alzheimer's Disease

8:30 – 9:20AM “Modulation of Amyloid Beta-Induced Toxicity by Ginkgo Biloba in an Animal Model of Alzheimer's Disease.”
Yuan Luo, Department of School of Pharmacy, University of Maryland

9:20 – 10:10AM “Immunotherapy for Alzheimer's Disease”
David Morgan, Department of Pharmacology and Molecular Therapeutics, University of South Florida

10:10 – 10:25AM Break

10:25 – 11:15AM “Development of BACE Inhibitors for the Treatment of Alzheimer's Disease”
Allen Reitz, Senior Research Fellow, Johnson & Johnson Pharmaceutical Research and Development, Editor, Current Topics in Medicinal Chemistry

11:15 – 12:05PM “Preclinical Studies of Novel Drugs for the Treatment of Alzheimer's Disease: Mouse to Monkey”
Jerry Buccafusco, Alzheimers Research Center, Medical College of Georgia

12:15 – 1:00PM Lunch

1:00 – 3:00PM Poster Presentations

3:00 – 5:00PM Platform Presentations (Limited space available, please get your request in early)

5:15 – 6:16PM Optional Tour of the Natural Products Center

6:30PM Banquet at The Downtown Grill

Tuesday November 7th

Neuropsychiatric Disorders: Novel Approaches

8:30 – 9:20AM “Melatonin Receptors as Targets for Modulation of Antidepressant-Like Responses”
Margarita Dubocovich, Department of Molecular Pharmacology, The Feinberg School of Medicine, Northwestern University

9:20 – 10:10AM “Development of Novel Antidepressant Compounds with Actions on Sigma Receptors”
Rae Matsumoto, Department of Pharmacology, University of Mississippi

10:10 – 10:25AM Break

10:25 – 11:15AM “Reexamination of the Importance of Norepinephrine and its Transporter in Depression”
Greg Ordway, Department of Pharmacology, East Tennessee State University

11:15 – 12:05PM “Allosteric Potentiation of Metabotropic Glutamate Receptor 5 and the M₁ Muscarinic Receptor: A Potential Therapeutic Direction for Schizophrenia”
Colleen Niswender, Department of Pharmacology, Vanderbilt University

12:15 – 1:00PM Lunch

1:00 – 3:00PM Poster Presentations

3:00 – 5:00PM Platform Presentations (Limited space available, please get your request in early)

5:15 – 6:30PM Awards ceremony and reception

6:30PM Evening on your own

Register on-line at: http://www.aspet.org/public/chapters/seps_chapter.htm

If you have questions, please contact: Larry Walker, 662-915-1005 or Cindy Farrar, 662-915-7330



ASPET, Divisions to Present New Awards at EB '07

ASPET, the Division for Drug Metabolism, and the Division for Cardiovascular Pharmacology, among them, will present six new awards at EB '07 in Washington, DC. ASPET will present the Julius Axelrod Award and three ASPET-ASTELLAS Awards in Translational Pharmacology. The Division for Drug Metabolism will present its Early Career Achievement Award. The Division for Cardiovascular Pharmacology will present the Benedict R. Lucchesi Distinguished Lectureship in Cardiac Pharmacology. Descriptions follow:

Julius Axelrod Award



The *Julius Axelrod Award* was established by the Catecholamine Club in 1991 to honor the memory of this eminent American pharmacologist who shaped the fields of neuroscience, drug metabolism and biochemistry and who served as a mentor for numerous eminent pharmacologists around the world. Effective with the 2007 award, ASPET has assumed responsibility for the *Julius Axelrod Award* and will continue to present it annually for significant contributions to understanding the biochemical mechanisms underlying the pharmacological actions of drugs and for contributions to mentoring other pharmacologists.

The award, which will be sponsored initially by contributions from Eli Lilly and Company, Wyeth Research, and Abbott Laboratories, consists of \$5000, registration to EB, travel expenses for the winner and spouse to EB, and a newly redesigned medal. The formal presentation of the *Julius Axelrod Award* will be made at the awards ceremony on Saturday, April 28, 2006, in the Washington Convention Center. The recipient will deliver the *Julius Axelrod Lecture* on Sunday, April 29, and will also be invited to give a less formal lecture at the dinner meeting of the Catecholamine Club.

While there are no restrictions on candidates for this award, the nominator must be a member of either ASPET or the Catecholamine Club. The award shall be made on the basis of originality and uniqueness of accomplishments throughout a long career distinguished by sustained, significant contributions to research and mentoring in pharmacology. The nominations will be reviewed by a committee chaired by Dr. David Sibley and comprised of Graeme Eisenhofer, Donna Wong, and Pat Sonsalla representing the Catecholamine Club, and Edward Morgan, Kim Neve, and Timothy Tracy representing ASPET.

Nominations for the *Julius Axelrod Award* are due in the ASPET office **October 15, 2006**, and must consist of the original and six (6) copies of: a letter of nomination describing the research and mentoring contributions to pharmacology of the candidate that make him/her eligible for this Award, a brief biographical sketch of the candidate, a list of individuals mentored by the candidate, and a copy of the candidate's CV and bibliography.



ASPET-Astellas Awards in Translational Pharmacology

ASPET will be making three (3) awards to recognize pharmacological research accomplishments that seek to extend fundamental research closer to applications directed towards improving health. The awards will be given to recognize those individuals whose research has the potential to lead to the introduction of novel pharmacologic approaches or technologies that may offer significant advances in clinical medicine in the future and to facilitate that translational process. The award is not intended to be simply an honorific for past work, but a recognition of ongoing work that will continue to contribute to human health. Funded by the Astellas Foundation, each award will consist of \$30,000 to be used in any way the investigator feels will further the goals described above, including, but not limited to, supplemental research funding, travel, training, or personnel.

There are no restrictions on nominees for this award with respect to age, nationality, position, or employment sector. The nominator, however, must be a member of ASPET. The applications will be reviewed by an ad hoc committee comprised of current and former members of ASPET Council and will be judged on the publication record of the applicant (significance, not length), the quality and impact of the published research cited in support of the nomination, the potential of the proposed future studies to advance clinical medicine through the introduction of novel pharmacological approaches to therapeutics, and the feasibility of the proposed research, given the size of the award.

The deadline for nominations is **October 15, 2006**. Nominations must be submitted electronically to markin@aspet.org and must consist of a two-page summary that details the importance of the candidate's work and how it meets the criteria of the award, two additional supporting letters (need not be from ASPET members), the candidate's CV and bibliography, a two-page statement from the candidate of his/her plans for moving his/her research forward toward clinical practice and how the award money would be used to further this goal, and up to five articles published or submitted for publication (either PDFs or links to the articles may be submitted).

Drug Metabolism Early Career Achievement Award

This award was established to recognize excellent original research by early career investigators in the area of drug metabolism and disposition. It is presented biennially in odd-numbered years. The award consists of \$1000, complimentary registration for EB, travel expenses for the winner, not-to-exceed \$1000 and a plaque. The winner of this award will present a lecture during the Division for Drug Metabolism's platform session describing his/her relevant research accomplishments. The winner will also be invited to publish a review article on the subject of the lecture in *Drug Metabolism and Disposition*.

Candidates for this award must be within 15 years of receiving their final doctoral degree. The primary criteria for the award is the level of excellence and originality of research in drug metabolism and disposition, conducted in any employment sector. Independence of thought, originality of approach, clarity of communication, and the impact of the work on the drug metabolism field will also be important considerations. The deadline for nominations for this award is **September 15, 2006**.



[Benedict R. Lucchesi Distinguished Lectureship in Cardiac Pharmacology](#)



The Division for Cardiovascular Pharmacology established this award to honor Dr. Lucchesi's lifelong scientific contributions to our better understanding and appreciation of the pharmacological treatment and prevention of cardiovascular disease and for his mentoring of countless prominent cardiovascular pharmacologists. It is presented biennially in odd-numbered years. The award consists of \$1000, complimentary registration for EB, travel expenses for the winner not-to-exceed \$2000, and a plaque. The winner of this award will present a lecture on recent advances in the field of cardiac and electrophysiology during the Cardiovascular Pharmacology Division's divisional programming.

There are no restrictions on institutional affiliation, nationality, or age of the candidate, but the recipient must be a member of ASEPT, as must be the nominator. For more information on nominating someone for the Benedict R. Lucchesi Distinguished Lectureship, please visit the web page for the Division for Cardiovascular Pharmacology, http://www.aspet.org/public/divisions/cardiovascular/lucchesi_award.htm. The deadline for nominations for this award is **October 15, 2006**.

It's that time of year again...

Your 2007 dues notice will be mailed this month.

Save time and a stamp by paying your dues online.

www.aspet.org

Click on "Online Dues Payment" in the Membership Section of the website.



Definitions of Categories of ASPET Membership

◆ **Regular Members:** Any doctoral level investigator who has conducted, and is the primary author on at least one publication of, an original study in the area of pharmacology published in a peer-reviewed journal is eligible for membership in ASPET. Exceptions may be made for someone who does not meet the degree requirement but who has made major research contributions to pharmacology. Dues for regular members are \$140/year. Regular members must be nominated by two (2) Regular or Retired ASPET members.

◆ **Affiliate Members:** An investigator who does not meet the requirements for Regular membership because of the lack of a degree or lack of publication is eligible to apply for Affiliate membership. Affiliate members receive all the same member benefits as Regular members except that they may not vote in ASPET elections. Dues for Affiliate members are \$105/year. Affiliate members must be nominated by one (1) Regular or Retired ASPET member.

◆ **Student Members:** Individuals who are enrolled in undergraduate, graduate, or professional degree programs are eligible for Student membership in ASPET. Student members receive all the same benefits as Regular Members except that they may not vote in ASPET elections. Individuals may remain in the Student Member category for up to two (2) years following completion of their research doctoral degree. Undergraduate students pay no dues. Dues for second year and above Student Members are \$30. Student members must be nominated by one (1) Regular or Affiliate ASPET member.

Sponsors should send an email or letter addressing the applicant's qualifications for ASPET membership directly to the ASPET office (rphipps@aspnet.org).

Regular Member Benefits (Dues \$140):

- Reduced page charges to publish in ASPET journals – pay \$35/page instead of \$70/page and save enough with one four-page article to pay your annual ASPET dues!
- Half-price color fees to publish color figures in ASPET journals
- Free full-text access to all five online ASPET journals, including all back issues
- Free subscription to *Molecular Interventions* (print) and *The Pharmacologist* (online)
- Reduced subscription rates for ASPET print journals
- Reduced registration fees for ASPET meetings
- Sponsorship of papers at the ASPET meeting
- Best abstract awards for young scientists at the ASPET meeting
- Free listing in the FASEB Directory
- Membership in multiple ASPET Divisions for no additional dues.

Affiliate Members (Dues \$105) have all the benefits of Regular Members except they may:

- Sponsor candidates for Student membership only.
- Not sponsor a paper for a non-member at a Society meeting.
- Not vote in Society elections.
- Not hold an elected office in the Society.

Student Members (Dues \$30) have all the benefits of Regular Members except they:

- Pay no dues their first year.
- Pay only \$30 annual dues thereafter. Undergraduate student members pay no dues and get their first graduate year free.
- Must have their papers at Society meetings sponsored by a member.
- May not vote in Society elections nor hold an elected office in the Society.

2007 Publication Subscription Rates for Members

All Society Members qualify for the following reduced print publication subscription rates:

- *Journal of Pharmacology and Experimental Therapeutics* (Monthly) - \$182/year
- *Pharmacological Reviews* (Quarterly) - \$77/year
- *Drug Metabolism and Disposition* (Monthly) - \$96/year
- *Molecular Pharmacology* (Monthly) - \$131/year
- *Molecular Interventions* (Bimonthly) – included with dues

APPLICATION INSTRUCTIONS:

Submit the completed Application for Membership form or use the online application form on the ASPET web site at <http://www.aspet.org/public/membership/membership.html>. Submit a current *curriculum vitae* including bibliography for Regular and Affiliate Membership. You may e-mail the CV to the ASPET Membership Coordinator, Robert Phipps, rphipps@aspnet.org.

Sponsor Statements: Submit a statement(s) of qualifications of the applicant from two Regular/Retired Members of ASPET for Regular Membership and from one Regular/Retired Member of ASPET for Affiliate Membership and Student Membership (Affiliate Members may also sponsor student applicants). In addition to statement certifying that the applicant is qualified for ASPET membership, sponsors please provide your own current address, phone, fax and email **It is the responsibility of the applicant to insure that these documents are submitted to the ASPET office.**





Membership Application

Application for:

- Regular Membership
- Affiliate Membership
- Graduate Student – Expected Date of Graduation: _____
- Undergraduate Student - Year: Fr Soph Jr Sr

HOW DID YOU HEAR ABOUT ASPET?

- Referred by a Mentor/Colleague
- Received ASPET Information by mail or email
- Internet (ASPET website)
- ASPET Journals
- EB/ASPET Annual Meeting
- Other:

Personal Information: *Please complete this section – type if possible*

Name and Address: _____ Telephone: _____
 _____ Fax: _____
 _____ E-mail: _____
 _____ Date of Birth (optional): _____

Education and Training:

Date and Degree	School	City/State/Country	Major Field

Professional Experience: *(Present position first) Please include dates, position, and organization*

Name, address and email of two sponsors: *(one sponsor for student and affiliate membership)*

Divisions: *Division membership is a benefit of ASPET membership and there is no additional charge to belong to a division. It is highly recommended that you join a division so that you may take full advantage of Society participation. Joining a division allows you to participate in creating the scientific program for the annual meeting, network with people in your field at mixers and divisional programs, and receive special notices and newsletters about items and activities of interest in your field. Be sure to pick a division!*

Indicate primary (1) and as many secondary (X) divisions to which you wish to belong:

- | | |
|---|--|
| <input type="checkbox"/> Division for Behavioral Pharmacology | <input type="checkbox"/> Division for Drug Metabolism |
| <input type="checkbox"/> Division for Cardiovascular Pharmacology | <input type="checkbox"/> Division for Molecular Pharmacology |
| <input type="checkbox"/> Division for Clinical Pharmacology, Pharmacogenomics, & Translational Medicine | <input type="checkbox"/> Division for Neuropharmacology |
| <input type="checkbox"/> Division for Drug Discovery, Development & Regulatory Affairs | <input type="checkbox"/> Division for Pharmacology Education |
| | <input type="checkbox"/> Division for Systems & Integrative Pharmacology |
| | <input type="checkbox"/> Division for Toxicology |

Paperwork Summary:

- Application Form (complete all sections)
- Statement of qualification for membership in ASPET and signatures from two sponsors for Regular membership and from one sponsor for Affiliate and Student membership. A letter or e-mail should be sent by the sponsor to the Membership Coordinator (rhipps@aspnet.org).
- Curriculum Vitae (include bibliography) for Regular and Affiliate membership

Applications are reviewed on a rolling basis. Please **DO NOT** send payment with your application. Upon membership approval, you will be sent a dues statement and welcome package.

Call or e-mail the ASPET Membership Department for additional information: 301-634-7135 / rhipps@aspnet.org.
 You may apply online at <http://www.aspet.org/public/membership/membership.html>